# INDEX TO VOLUME 177

## Author Index


Abdulkarim, A. S., 409
Abel, L., 133
Abzug, M. J., 1772
Ackers, M.-L., 1588
Adams, S., 827
Adderson, E. E., 1116
Adegbola, R. A., 1758
Adler, G., 1124
Adler, S. P., 209
Adrian, D. L., 827
af Geijersstam, V., 1710
Afzal, M. A., 265
Afzelius, P., 1733
Agasino, C. B., 1104, 1107
Agnew, D. G., 754
AHF Study Group, 277
Åhman, H., 1614
AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group, 48
AIDS Clinical Trials Group Protocol 175 Team, 617
AIDS Vaccine Evaluation Group, 301, 310
Ait-Khaled, M., 1097
Aladdin, H., 331
Al-Attar, J., 501
Albert, M. J., 1594
Alexander, D., 481
Alexander, W. J., 231
Alfandari, S., 1776
Alfieri, C., 1087
Allen, G., 1260
Alper, C. M., 1260
Al-Sherbiny, M., 1364
Alter, H. J., 539
Alves, D., 1139
Ambrosio, A. M., 277
Ambroziak, J., 213
Ambyaye, A., 409
Ampurdanés, S., 839
Amstey, M. S., 1772
Anders, R., 1664
Andersen, J., 761
Andreu, D., 1080
Andrus, L., 889
Angel, J., 455
Angel, J. B., 898
Angeloni, A., 1715
Ansari, A., 57
Anttila, M., 1614
Anwar, D., 783
Aoki, F. Y., 252
Aoki, K., 1701
Aoun, K., 1687
Apgar, C. L., 855
Arcoleo, F., 489
Arens, M., 217
Arichi, T., 72
Armijos, R. X., 1352
Armstrong, P. M., 1422
Arnó, A., 1080
Arpino, R., 1266
Arvin, A. M., 1701
Ashley, R., 1188
Ashton, F. E., 1754
Astemborski, J., 539
Augustine, N. H., 1418
Aukrust, P., 586, 1091
Aviles, H., 1352
Azimi, P. H., 790
Baarsma, S. G., 484
Badaró, R., 1339
Bailey, R. L., 256
Baker, M. G., 497
Baldanti, F., 823
Balfour, H. H., Jr., 823
Balkau, B., 492
Ballou, W. R., 1664
Balslev, U., 1214
Barbeau, P., 1502
Barber, B. H., 551
Barbera, C., 489
Barcova, M., 905
Barozzi, P., 520
Barrero Oro, J. G., 277
Barré-Sinoussi, F., 1770
Barrett, D., 1766
Barrett, T. J., 1588
Barry, P. A., 446
Bartelink, A. K. M., 1401
Barthold, S. W., 395, 737
Bartlett, J. A., 231
Baseler, M., 579
Bass, D., 455
Bassily, S., 796
Bayne, L., 931
Becker, K., 1023
Becquart, P., 1770
Beers, M. F., 182
Behr, M., 1696
Bélec, L., 1770
Belgaumi, A., 1194
Belli, D. C., 1413
Bellini, W. J., 204
Belshe, R. B., 310, 1230, 1394
Bengtsson, K. L., 1266
Benson, D. R., 1339
Benton, P. A., 1727
Berardi, C. J., 1247
Berens, R. L., 746, 1128
Berger, J., 1138
Bergeron, M. G., 188, 355
Bermudez, L. E., 914
Bernal, I., 889
Bernander, S., 247
Bernstein, D. I., 1394
Berry, P. S., 231
Bertolotti, D., 807
Berzofsky, J. A., 72
Bethel, J., 1730
Bethell, D. B., 778
Bhoomkar, A., 167
Bibb, W. F., 1588
Biemba, G., 1064
Billmann, L., 998
Bingen, E., 642
Biron, K. K., 823
Bistoni, F., 347
Bitzan, M. M., 955
Blaak, H., 600
Black, S. M., 692
Blackbourn, D. J., 213, 470
Blanche, S., 1737
Blauw, B., 451
Blondeau, C., 1290
Bloor, S., 1521
Bockman, K. W., 231
Bode, G., 1124
Boerman, O. C., 1398
Bohnsack, J. F., 1116
Boivin, G., 355
Bolan, G., 931, 1766
Boner, W., 264
Bonjoch, A., 1080
Bonten, M. J. M., 378
Bonville, C. A., 1458
Borg-von Zepelin, M., 1057
Boschini, A., 848
Bossink, A. W. J., 81
Böttger, E. C., 1573
Bouvenot, G., 492
Bowden, R. A., 1775
Boyer, C. B., 1766
Boyle, M. D. P., 991
Bradford, W. Z., 1104
Braga, É. M., 1132
Brahimi, N., 642
Braxton, C. C., 793
Brechot, C., 848
Brenner, H., 1124
Brenner, R. A., 790
Bresee, J. S., 13
Briem, H., 683
Briesacher, M. R., 1116
Briggiler, A. M., 277
Britt, W. J., 446
Britto, P., 557
Broelsch, C. E., 1378
Brogan, T., 1770
Brommer, E., 451
Brooks, G. F., 1766
Broome, C. V., 683
Brouwer, M., 600
Brown, B. A., 1573
Brown, D., 1719
Brown, F. M., 796
Brown, J. J., 97, 651, 1120
Brown, P., 1143
Bryant, M., 1394
Bryla, D. A., 383
Bucci, J. G., 18
Buescher, C., 881
Buessow, S., 1083
Bukh, J., 855
Burdelski, M., 1378
Burgard, M., 1737
Burke, J. F., 1622
Burke, R. L., 481
Burns, J. M., Jr., 1345
Burt, D., 1266
Buscaglia, C. A., 431
Busch, M. P., 1221
Buurman, W. A., 778
Bwayo, J., 551
Byington, R., 625
Byrne, G. I., 725
Caiaffa, W. T., 611
Calderon, G., 529
California Collaborative Treatment Group, 595
Cameron, D. N., 1405
Cameron, D. W., 898
Camerota, A. J., 668
Campa, H. C., 683
Campbell, A. E., 256
Campbell, L. A., 1322
Campetella, O., 431
Canadian HIV Trials Network Protocol 010 Study Group, 252
Canfield, D. R., 1247
Carbon, C., 492
Cardosa, M. J., 778
Carlino, U. B., 1120
Carlone, G. M., 683
Carman, W. F., 264
Carpentier, L., 1087
Casadevall, A., 1639, 1647

Cassone, A., 807
Castillo, R., 1036
Castro, C., 1036
Caterino-de-Araujo, A., 1136
Cave, M. D., 1104
Çelik, J., 247
Centurion-Lara, A., 1036
Cerimele, D., 1715
Cesbron-Delauw, M.-F., 746
Cha, T.-A., 1143
Chakrabarti, P., 1345
Chang, M.-H., 1202
Chanock, R. M., 1073
Chapman, S., 1533
Charness, M. E., 401
Chastang, C., 1373
Chen, D.-S., 1202
Chen, H., 1682
Chen, P.-J., 1202
Chernoff, D., 1746
Chhatwal, G. S., 1600
Chi, E. Y., 1437
Chidiac, C., 1776
Child, A. H., 388
Childers, T. A., 18
Cho, I., 1394
Chodosh, J., 1194
Chollet, L., 235
Chu, K. M., 1314
Church, L. W. P., 1664
Church, P. J., 1762
Cillari, E., 489
Clancy, C. J., 425
Clark, B. D., 1622
Clark, P., 790
Clarke, M. J., 13
Clarke, R. C., 1139
Clausen, C., 1774
Clemens, J. D., 790, 796
Clements-Mann, M. L., 1230
Clendennin, N., 1533
Clotet, B., 1080
Clough, L., 1746
CMV Retinitis and Viral Resistance Study Group, 770
Coakley, D., 48
Cockerill, F. R., III, 409, 1773
Cohen, J. I., 293, 1390
Cohen, M. S., 224, 1742
Cohn, S., 611
Colbach, C., 459
Cole, K. S., 1247
Collier, A. C., 40, 320, 1188
Collins, F., 1030, 1332
Colman, K., 264
Conant, M., 1533
Conejero, M., 1080
Connor, R. I., 310
Connors, M., 579
Conti, S., 807
Conway, B., 1514
Conway, D. J., 256
Cook, R. S., 874
Coombs, R. W., 40, 320, 557
Coonrod, D., 1188
Cooper, D., 48
Corachán, M., 1409
Corey, L., 301, 310, 320, 1069, 1188, 1230
Cornelissen, J. G. C., 484
Correlates of HIV Immune Protection Group, 310
Corriveau, C. C., 116
Corstens, F. H. M., 1398
Cortes, N. J., 977
Costagliola, D., 1737
Costes, O., 235
Cotton, D., 761
Cottoni, F., 1715
Coulibaly, I.-M., 65
Coulthart, M. B., 1754
Cowles, M. K., 761
Coyle, C., 515
Coyle, S. M., 793
Crabb, J. H., 662
Crampton, S. L., 1746
Crane, C. M., 1104
Crawford, S., 477
Creasey, A. A., 668
Criscione, L., 242
Critchlow, C. W., 571
Crotchfelt, K. A., 417
Crowe, J. E., Jr., 1073
Crutcher, J. M., 1664
Cryz, S. J., 1762
Cunningham, A. L., 827
Curfs, J. H. A. J., 175
Curiel, T. J., 746, 1128
Currier, J., 595
Curtis, J., 1429
Curtis, M., 1041
Cusack, T. M., 881
Daftarian, P., 898
Dagan, R., 1003, 1425
D'Agostino, P., 489
Dai, X., 881
Daley, C. L., 1107
Daly, C. C., 224
Dam-Larsen, S., 1733
Damrow, T., 1588
Danis, V. A., 827
Danner, R. L., 116
D'Aquila, R. T., 40, 617, 1549
Davenny, K., 1480
Davis, C., 1046
Dawson, J. E., 1422
Day, N. P. J., 778
Dean, D., 1314
de Béthune, M.-P., 1521
Deelder, A. M., 1433
de Groot, M. C. M., 81
de Groot, R., 102
De Gruttola, V., 40, 761
Dehaumont, P., 155
de Kloet, E. R., 451
Delehanty, A., 662
Dellagi, K., 1687
del Portillo, H. A., 511
Demacker, P. N. M., 1401
de Man, R. A., 1382
DeMasi, R., 231
Denamur, E., 642
de Quirós, J. C. L. B., 579
Deresinski, S. C., 914
DeRouen, T., 1188
Derouin, F., 1373
Deschênes, J., 252
de Silva, A. M., 395
Desjardins, P., 642
Desportes-Livage, I., 1373
de Taisne, C., 1664
de Wolf, F., 600
Dezzutti, C. S., 1489
Diaz, C., 1480
Diaz, P. S., 1405
Diaz-Mitoma, F., 898
Di Bella, G., 489
DiCristina, J., 1405
Dierich, M. P., 905, 1057
Dillard-Telm, S., 1247
Dillner, J., 1710
Dithmer, D., 1766
Dittmer, U., 1771
Division of AIDS Treatment Research Initiative 003 Study Group, 1730
Dix, L., 57
Dolin, R., 310, 1230
Domachowske, J. B., 1458
Domeika, K., 714
Domeika, M., 714
Donnelly, C. A., 819
Dooley, D. P., 951
Dopazo, J., 839
Dornan, E. S., 264
Doyle, L. J., 677
Doyle, M. K., 242
Doyle, W. J., 1260
Dragavon, J., 320
Driver, C., 1138
Duan, L., 1073
Dubois, V., 1502
Dudez, T. S., 1413
Duliege, A.-M., 1230
Dunn, J. P., 770
Dunne, M. W., 595
Duperval, R., 252
Duraisingh, M. T., 1429
Durakovic, C., 1514
Duran, M., 1533
Dusheiko, G., 1719
Dutronc, H., 1502
Dwyer, D. M., 998
Dyer, J. R., 224, 1742
Dyer, K. D., 1458
Dykes, J., 683
Dziarski, R., 1629
Eastman, P. S., 557
Efstratiou, A., 786
Ehrlich, L. C., 260
Eigler, A., 774
Einsele, H., 519
Eintracht, S., 473
Ekpini, E., 65
Elbeik, T., 617, 625
El Gengehi, N., 1364
El-Hajj, H., 1104
Eling, W., 1358
Elion, J., 642
Elliott, J. A., 998
El-Masry, N. A., 796
El Ridi, R., 1364
Embree, J., 551
Emerson, S. U., 855
Emery, V. C., 57
Endres, S., 774
Enger, C., 770
English, R. V., 18
Engstrand, L., 247
Enhorning, G., 269
Ennis, J. G., 1443
Enria, D. A., 277, 592
Entenza, J.-M., 146
Erhardt, S., 774
Erice, A., 823
Eron, J. J., Jr., 224, 1742
Escherichia coli O157:H7 Study Group, 962
Eschwège, E., 492
Eskola, J., 1614
Evans, C. A. W., 1582
Evans, G. S., 977
Everding, A. S., 1023
Excler, J.-L., 1230
Faggioni, A., 1715
Fairchild, R., 459
Falagas, M. E., 459
Falloon, J., 579
Falsey, A. R., 463
Fanti, F., 807
Farber, B. F., 501
Farley, L., 1664
Farouk, F., 1364
Farshy, C. E., 167
Farzadegan, H., 611
Fast, P. E., 310, 1230
Fattovich, G., 264
Fauci, A. S., 1332
Feddersen, R., 1696
Feihl, F., 127
Feinberg, J. E., 48, 57
Feldmesser, M., 1639
Feng, N., 455
Feng, P., 1750
Feng, S., 737
Ferrieri, P., 790, 998
Feuillade, M. R., 277
Fikrig, E., 395, 737
Filion, L. G., 898
Fink, M. P., 668
Finkel, Y., 247
Finn, A., 977
Finnish Study Group for Antimicrobial Resistance, 786
Fischer, L., 1378
Fischl, M. A., 40, 761

Fiscus, S. A., 224, 617, 625, 1742
Fish, D., 737
Flanigan, M., 579
Fletcher, J. M., 1465
Fleury, H. J. A., 1502
Flobbe, K., 778
Flood, J. M., 931
Flosdorff, A., 991
Folks, T. M., 65, 1221
Fontes, C. J. F., 1132
Forman, M., 770
Forns, X., 839
Forthal, D., 595
Fortney, K., 1608
Foung, S. K. H., 855
Fox, C. H., 1497
Francioli, P., 146
Fransen, S., 1514
Frasch, A. C. C., 431
Fraser, D., 1003
Freedman, D. J., 662
Freedman, V. H., 1563
Freeman, R., 459
Freeman, W. R., 1182
Freeze, T., 1046
Freiji, R., 1554
Frenkel, L. M., 557
Friedland, J. S., 1582
Friedman, C. R., 1138
Friedman, M. G., 1425
Frischkorn, K., 1573
Frøland, S. S., 586, 1091
Fry, J., 48, 57
Fryauff, D. J., 1762
Fugger, L., 1214
Fujihashi, K., 26
Furze, J. M., 874
Gallichan, W. S., 1155
Gam, A. A., 196, 815
Gan, Y.-j., 1194
Garin, B., 1770
Gascón, J., 1409
Gaur, L. K., 5
Gaydos, C. A., 417
Gaynor, R., 941
Gea-Banacloche, J. C., 579
Gekker, G., 260
Gelfand, J. A., 1622
Georgio, D., 523
Gerloni, M., 807
Gerna, G., 823, 1170
Gerstoft, J., 331, 1214
Ghadirian, P., 1087
Giacobbe, K. D., 825
Gibbs, P. H., 277
Gill, M. J., 48
Gilliam, B. L., 1742
Gilmour, P. S., 1073
Giorgi, J. V., 1083
Giuntelli, S., 848
Glass, R. I., 13
Goguel, J., 1373
Gold, B. D., 955
Goldbaum, G., 571
Goldblatt, D., 1112
Goldblatt, S., 881
Goldman, D. L., 1647
Goldstein, H., 337
Goletti, D., 1332
Gómez-Cano, M., 1221
Goode, B., 1588
Gor, D., 57
Gordeuk, V. R., 1064
Gorny, M. K., 889
Gorse, G. J., 301, 310, 1230
Goulet, V., 155
Goulston, C., 1100
Govindarajan, S., 855
Gradoni, L., 1339
Graham, B. S., 301, 310, 1230
Graham, S., 231
Granlund, M., 967
Gravallese, E. M., 242
Grayston, J. T., 1322
Green, M., 504
Green, T. A., 1221
Green, W., 1696
Greenberg, A. E., 65
Greenberg, D., 1425
Greenberg, H. B., 455
Greene, K. D., 962
Greenwood, B. M., 1758
Greten, H., 1378
Griffin, P. M., 962, 1588
Griffith, B. P., 617, 625
Griffiths, E., 683
Griffiths, P. D., 48, 57
Groeneveld, A. B. J., 81
Grogan, J. L., 1433
Groothuis, J. R., 467
Gruber, A., 1057
Grundy, J. E., 1465
Gu, X., 1682
Guardati, M. C., 1308
Guerrant, R. L., 88, 754
Guillemot, D., 492
Guito, K. P., 1664
Günther, S., 1378
Gupta, D., 1629
Gupta, S., 819
Guris, D., 1041
Guroy, M. E., 931
Gwanzura, L., 481
Haagsma, E. B., 1382
Haas, D. W., 1746
Haberland, M., 1162
Hack, C. E., 81
Hacker, U. T., 774
Hadengue, A., 783
Hadziyannis, S., 264
Hahn, B. L., 812
Hahn, J. A., 1107
Haikin, H., 1425
Hall, B. T., 1664
Hall, E., 796
Hallahan, C., 579
Hallas, G., 786
Haller, O., 1162
Halsey, N. A., 277
Halstead, S. B., 221
Hammer, S. M., 40, 617, 625, 761
Hammerschlag, M. R., 720
Handfield, J., 355
Hanna, B. A., 824
Hansen, J.-E. S., 1733
Harms, E., 1023
Harrich, D. A., 941
Harrigan, P. R., 1521
Harris, M., 1514
Harrison, L. H., 277, 998
Harrison, T. J., 1719
Hartmann, G., 774
Harvie, P., 188
Haslov, K., 730
Haubrich, R., 595
Haug, C. J., 586
Hauptman, P., 417
Havlir, D. V., 595
Hawes, S. E., 571
Hayden, F. G., 863, 1260
Hayden, M. K., 378
Hayes, P. S., 1588
Hazenberg, M. P., 102
Hebart, H., 519
Heisey, D. M., 1296
Henderson, W. R., Jr., 1437
Hendricks, A., 1533
Hendrickx, A. G., 446
Heneine, W., 65, 1221
Herdman, D. S., 508
Heringlake, S., 1723
Herman, S. A., 557
Herrmann, M., 1023
Hershow, R., 1480
Hertogs, K., 1521
Heston, L., 1715
Hijmans, A., 1401
Hill, A. V. S., 1664
Hill, E. L., 543
Hill, H. R., 1418
Hill, T. J., 1451
Hiltke, T. J., 1608
Hinloopen, B., 451
Hirayama, K., 1682
Hirji, K., 1083
Hiroi, T., 26
Hirschel, B., 783, 1497
Hirschl, A. M., 803
Hittinger, G., 235
Hjelle, B., 1696
Ho, D. D., 1533
Hoa, V. L., 133
Hocini, H., 1770
Hodzic, E., 395, 737
Hoepelman, A. I. M., 260
Hoffman, I. F., 224, 1742
Hoffman, S., 1664
Hoffman, S. L., 1762, 1777
Hofmeister, E. K., 409
Hogerman, D. A., 467
Hoiby, E. A., 683
Hoijer, M. A., 102
Holder, V. P., 1194
Holland, F. J., 48
Holland, G. N., 48
Holland, M. J., 256
Hollinger, F. B., 1480
Holly, E. A., 361
Holman, R. C., 13
Holmes, K. K., 571
Holmgren, J., 1594
Holst, J., 683
Honkoop, P., 1382
Hood, A. F., 1608
Hooks, J. J., 293
Hooton, T. M., 320
Hopewell, P. C., 1104, 1107
Hopkins, M. K., 409
Hopkins, W. J., 1296
Horii, T., 1664
Horne, C., 5
Horsburgh, C. R., Jr., 730
Horton, J., 1373
Hoskins, W., 1533
Houghton, R. L., 1339
Howell, M. R., 417
Hsieh, R.-H., 1230
Hsueh, F., 470
Hu, S., 260
Huang, W. M., 951
Huesca, M., 955
Hufert, F. T., 1162
Hughes, J. P., 320
Hughes, M. D., 40, 617, 625, 1549
Hughes, S. P. F., 1582
Hughes, W. T., 1046
Hultgren, C., 264
Hunninghake, G. W., 1275
Hunsmann, G., 1771
Hunt, J. C., 539, 1723
Huovinen, P., 786
Hur, J. K., 209
Hurley, A., 1533
Hurwitz, S., 48
Hutwagner, L., 1588
Hwang, J., 595
Ijdo, J. W. I., 737
Imaizumi, M., 519
Imaoka, K., 26
Ismail, J., 1405
Ismail, R. B., 1687
Itoh, M., 1682
Itoh, Y., 1475
Ivanoff, S., 1737
Iversen, A. K. N., 1214
Jabs, D. A., 770
Jackson, J. B., 617, 625
Jackson, R. W., 1332
Jackson, S., 1230
Jacobs, B. C., 102
Jacobson, M. A., 48
Jacquet, C., 155
Jaeger, A. S., 730

Jaffar, S., 1758
Jahn, G., 519
Jallow, O., 256
Janini, L. M., 227
Japour, A., 617, 625
Jaussaud, R., 1290
Jay, N., 361
Jaye, A., 1282
Jelinek, T., 774
Jellis, J., 1582
Jenison, S., 1696
Jensen, T., 1214
Jertborn, M., 796
Jiang, X., 881
Jin, Y., 1629
Jimenez de Anta, M. T., 1409
John, G. C., 34
Johnson, J., 231
Johnson, J. R., 97, 651, 1120
Johnson, R. P., 1139
Johnson, V. A., 40, 1549
Johnson, W. M., 1754
Jollick, J., 217
Joncas, J., 1087
Jongsakul, K., 800
Jonsdottir, K., 683
Jordan, H. L., 18
Jorgensen, J. H., 951
Jou, A., 1080
Jou, C., 1723
Kacani, L., 905
Kahane, S., 1425
Kahl, B., 1023
Kaiser, A. B., 701
Kaiwar, R., 1143
Kalayoglu, M. V., 725
Kalinina, T., 1378
Kantele, A., 1594
Kantele, J. M., 1594
Kantipong, P., 800
Kantor, F. S., 395
Kao, J.-H., 1202
Kapczynski, D., 683
Kaplan, G., 1563
Karavellas, M. P., 1182
Karch, H., 955, 1750
Karmali, M. A., 955
Kaslow, D. C., 1664
Kataja, J., 786
Katavolos, P., 737, 1422
Katopodis, N. F., 337
Katz, B., 1608
Katzenstein, D. A., 40, 481, 617, 625, 1100
Kavlick, M. F., 1506
Kawabata, S., 26
Kawasaki, S., 519
Käyhty, H., 1614
Kazatchkine, M., 1770
Kazembe, P., 224, 1742
Keefer, M. C., 301, 310, 1230
Keithly, J. S., 1443
Kelley, C., 1030
Kelsey, S. M., 107
Kemp, S. D., 1521
Kemper, C. A., 914
Kennedy, R. C., 1727
Kenney, R. T., 815
Kent, M., 515
Kent, S. J., 1771
Keown, P., 5
Kern, E. R., 543, 1143
Kernodle, D. S., 701
Kertesz, D. A., 1754
Kester, K., 1664
Keuter, M., 175
Khokha, N. D., 1773
Kibur, M., 1710
Kikuchi, M., 1682
Kilmarx, P. H., 677
Kim, A., 337
Kim, J. O., 368
Kim, J. P., 855
Kim, Y. S., 692
King, J. C., Jr., 1394
King, S. J., 467
Kinter, A., 1332
Kirchgatter, K., 511
Kitchen, V. S., 1386
Kiviat, N. B., 571
Kiyono, H., 26
Klausner, J. D., 161, 1766
Klein, M., 1266
Klempner, M. S., 401
Kluft, C., 451
Klugman, K. P., 1003
Knapp, J. S., 677
Kobzik, L., 986
Koch, H. G., 1023
Koduri, P. R., 1773
Koehler, J., 1104
Koelle, D. M., 543
Kolbert, C. P., 409
Kollmann, T. R., 337
Konadu, E. Y., 383
Konno, T., 519
Koornhof, H., 473
Korber, B. T., 310
Koskela, P., 1710
Kotloff, K., 1394
Kotzin, B. L., 746
Koutsky, L., 320
Krakauer, T., 1013
Kralian, S., 417
Kreiss, J. K., 34
Kreiswirth, B. N., 1138
Kremsner, P. G., 1433
Kress, Y., 1639
Krettli, A. U., 1132
Krieger, J. N., 320
Krug, E. C., 1128
Krzych, U., 1664
Kubotá, M., 26
Kullberg, B. J., 175
Kumapley, R., 1773
Kumar, A., 898
Kumar, S., 1664
Kuo, C.-c., 1322
Kuppermann, B. D., 1176
Kurichh, A., 1266
Kutlin, A., 720
Kuypers, J., 571
Kwiatkowski, D., 778
Labigne, A., 803
Lafeuillade, A., 235
Lafon, M.-E., 1502
LaFon, S., 1046
Lagos, R., 1394
Lagrange, P. H., 133, 1554
Lal, A. A., 437
Lal, R. B., 437, 1489
Lalonde, R., 355
Lalvani, A., 1664
Lambert, J. S., 310
La Montagne, J., 3
Lampel, K. A., 1750
Lampinen, T., 571
Lanar, D. E., 1664
Landesman, S. H., 1480
Lane, H. C., 579
Lang, J., 1290
Lap, V. D., 133
Lapointe, N., 1087
Larder, B. A., 1521
Larkin, V. A., 668
La Rosa, M., 489
Larsen, A. R., 1214
Lathey, J. L., 617, 625
Laverman, P., 1398
Lawrence, W., 543
Lawson, K. M., 1465
Le, T. P., 1777
Leahy, E., 1588
Lecordier, L., 746
Lederman, M. M., 1746
Lee, D.-H., 889
Lee, D. R., 1727
Lee, F. K., 1554
Lee, W., 320
Lee, Y. J., 796
Lefrère, J.-J., 1541
Leguizamón, M. S., 431
Lehner, T., 26
Lehtinen, M., 1710
Leib, S. L., 692
Leisenring, W., 1775
Lemieux, C., 252
Lendvai, N., 1647
Lennette, E. T., 213
Lennon, D. R., 497
Lensen, A., 1358
Leonard, J. M., 898
Lepri, A. C., 331
Lerable, J., 1541
Lerma, J. G. G., 1221
Leste-Lasserre, T., 1737
Levi, M., 793
Levin, J., 388
Levine, W. C., 167
Levis, S. C., 277, 529
Levy, J. A., 213, 470
Lewis, J. S., 167
Lewis, P., 34
Li, J. L., 221
Li, Q.-Q., 812
Li, Z., 1030
Liang, Z., 1647
Liaudet, L., 127
Libonati, J. P., 998
Lien, E., 586
Lienard, M., 1290
Lima, A. A. M., 88, 754
Limansky, A. S., 1308
Lin, F.-Y. C., 790
Lin, H.-H., 1202
Lin, S.-F., 1715
Lin, S. R., 242
Lingwood, C. A., 955
Lior, H., 1139
Lipovsky, M. M., 260
Lipschik, G. Y., 182
Lissner, R., 955
Liu, D.-P., 1202
Liu, W., 1176
Liu, X.-P., 1660
Lloyd, A. R., 827
Löffler, J., 519
Loomans, H. J., 812
López-Labrador, F.-X., 839
Lorentzen, D. F., 1296
Louzir, H., 1687
Lowry, S. F., 793
Luciw, P. A., 446
Lukasser-Vogl, E., 1057
Lukehart, S. A., 1036
Luo, C.-c., 227
Luppi, M., 520
Lutfey, M., 1138
Lyall, E. G. H., 1097
Lyles, C. M., 611
Lynne, J. E., 1083
Lyons, S. F., 473
Mabey, D. C. W., 256
Mabeza, G., 1064
MacCormac, L. P., 1465
Macdonald, J. C., 1182
MacDonald, K. S., 551
MacGregor, R. R., 48
MacWilliam, L., 5
Madara, P. J., 116
Maeda, Y., 1207
Magera, J. M. H., 409
Magill, A., 1664
Magliani, W., 807
Magnusen, A. F., 1282
Magnusson, M., 730
Mahmoud, A. A. F., 3
Mahon, B. E., 1588
Maida, M., 1742
Maison, P., 492
Maiztegui, J. I., 277
Mäkelä, P. H., 1594
Makristathis, A., 803
Maldonado, R., 1352
Malinoski, F. J., 634
Malley, R., 986

Maloney, K., 962
Maneval, D. R., 662
Mangiafico, J. A., 634
Mannoor, K., 1594
Manns, M. P., 1723
Mansinho, K., 65
Marasca, R., 520
Marchal, F., 1497
Marchewka, M. J., 1443
Mårdh, P.-A., 714
Maretzki, C. H., 737
Margolick, J. B., 611
Margolis, T. P., 1176
Mariotti, M., 1541
Markert, M., 127
Markowitz, M., 1533
Marrakchi, H., 1687
Marschner, I. C., 40, 761
Marsh, B. J., 730
Marsh, K., 819
Marshall, R., 539
Marthas, M. L., 1247
Martin, D. F., 1176
Martin, D. J., 473, 921
Martin, D. R., 497
Martin, J. M., 504
Maryland Emerging Infections Program, 998
Masala, M. V., 1715
Mascola, J., 1230
Maslow, J. N., 651
Mastronarde, J. G., 1275
Mathiesen, L., 1733
Mathy, S., 642
Matson, D. O., 881
Matsushima, K., 1275
Matta, M., 1770
Matthews, T., 301
Matthews, T. J., 310, 1230
Matud, J. L., 1083
Mayers, D., 1730
Mbori-Ngacha, D., 34
McCarthy, D., 523
McClain, D. J., 634
McClure, M. O., 1097
McCormack, P., 889
McCutchan, J. A., 595
McElrath, M. J., 301, 310, 1230
McEwen, S. A., 1139
McFarland, W., 481, 1100
McGee, L., 1003
McGhee, J. R., 26
McGrath, D., 459
McHarg, K., 217
McKee, K. T., Jr., 277
McSherry, G. D., 557
Meddows-Taylor, S., 921
Mehta, S. J., 1326
Meier, P. A., 951
Meis, J. F. G. M., 175
Meissner, D., 1723
Melby, P. C., 1687
Melief, M.-J., 102
Merigan, T. C., 477
Merires, M., 1003
Mestecky, J., 1230
Meyer-König, U., 1162
Mican, J. M., 579
Michiels, J.-F., 1373
Mikloska, Z., 827
Milano, S., 489
Miller, C. J., 26, 1247
Miller, E., 1112
Miller, G., 1715
Miller, J. J., 107
Miller, M., 252
Miller, R. D., 1326
Miller, V., 1521
Minami, M., 1475
Minor, P. D., 265
Mintz, E. D., 1041, 1405
Mitchell, L. A., 5
Mitchell, S., 167
Mitsuya, H., 1207, 1506
Miyamura, T., 284
Mizuta, K., 519
Moazed, T. C., 1322
Modaï, J., 1373
Modern, P. A., 825
Mofenson, L. M., 1480
Mohammed, Z., 551
Molina, J.-M., 1373
Molinari, G., 1600
Monari, C., 347
Monick, M. M., 1275
Montaner, J. S. G., 1514
Montefiori, D. C., 310, 1247
Montelaro, R. C., 1247
Moody, S. A., 1260
Moore, R. D., 754
Moore, S. D., 182
Morand-Joubert, L., 1541
Moreillon, P., 146
Morein, B., 1266
Morikawa, S., 284
Morris, A., 1719
Morris, A. J., 425
Morris, L., 473
Morris, S., 1030
Morrison, D. C., 1302
Morse, L. S., 1182
Morzunov, S. P., 529
Mourich, D. V., 213
Mouzin, E., 1762
Moyse, C., 155
Mukaida, N., 1275
Mukherjee, J., 1647
Mulder, L., 1358
Mulholland, E. K., 1758
Muller, E., 501
Müller, F., 586, 1091
Mulligan, M. J., 310
Mullins, J. I., 1214
Munsiff, S. S., 1138
Muotiala, A., 786
Murakami, Y., 1475
Murphy, B. R., 1073
Murray, G., 355
Murray, H. W., 815
Musser, J. M., 1773
Muyombwe, A., 188
Nader, S., 1701
Nagano, N., 1116
Nagano, Y., 1116
Nagelkerke, N. J. D., 551
Nagelkerken, L., 451
Nahlen, B., 819
Nahmias, A., 1554
Nakazawa, T., 72
Namperumalsamy, P., 1314
Nariuchi, H., 1674
Nash, P. B., 1128
Nataro, J. P., 88, 662
Nathan, C., 378
Nauwynck, H., 1076
Ndinya-Achola, J., 34, 551
Nduati, R., 34
Neal, S. W., 677
Neeleman, C., 1401
Negro, F., 783
Nelson, G. O., 634
Nelson, K. E., 539
Nepom, G. T., 5
Nesin, M., 707
Nestler, J., 1696
Netea, M. G., 175, 1401
Netski, D., 523
Neva, F. A., 196
Newland, A. C., 107
Newman, R. D., 754
Ngatia, I., 551
Nguyen, M. H., 425
NIAID AIDS Clinical Trials Group Protocol 241 Virology Team, 1549
NIAID AIDS Vaccine Evaluation Group, 1230
Nielsen, C., 1733
Nielsen, J. O., 1733
Nielsen, S. D., 1733
Niesters, H. G. M., 1382
Nishioji, K., 1475
Njenga, S., 551
Nkata, E., 224
Nokleby, H., 683
Norgard, M. V., 941
Norgren, M., 967
Norimatsu, M., 1302
Normark, S., 247
Nothdurft, H. D., 774
Nussenblatt, R., 293
Nyoka, S., 473
Öberg, L., 967
Oberti, J., 133
Ockenga, J., 1723
Ockenhouse, C. F., 1664
Okanoue, T., 1475
Olivier, M., 188
Olivo, P. D., 217
O'Mara, E. M., Jr., 1608
Oneta, M., 848
Onyi, G. O., 1573
Osman, A., 1364
Osterhaus, A. D. M. E., 484, 1382
Otto, S., 1378
Ouellette, M., 188
Overbaugh, J., 34
Owen, S. M., 437
Owens, S., 48
Oyen, W. J. G., 1398
Paavonen, J., 714
Palazzetti, B., 347
Palefsky, J. M., 361
Palmer, A., 819
Palmer, A. L., 1772
Palmer, J., 1143
Pancino, G., 1737
Pantaleo, G., 1497
Paoletti, E., 1230, 1664
Papadopoulou, B., 188
Paradiso, P. R., 467
Parashar, U. D., 13
Parato, K., 898
Pardi, G., 848
Pari, G. S., 523
Parke, J. C., Jr., 383
Parsonnet, J., 825
Passaro, D., 161
Pastore, F. D., 1413
Patick, A., 1533
Patla, V., 668
Pattamadilok, S., 204
Patterson, J. E., 951
Pattishall, E., 1046
Pauwels, R., 1521
Paxton, H., 800
Pedersen, B. K., 331
Pediatric AIDS Clinical Trials Group Protocol 076 Study Group, 557
Pedneault, L., 1087
Peeling, R. W., 256
Pellegrin, I., 1502
Pellegrin, J.-L., 1502
Pensaert, M., 1076
Peralta, J. M., 227
Percivalle, E., 1170
Perelson, A. S., 863
Perides, G., 401
Perkins, B. A., 683
Perlman, D. C., 1138
Perret, C., 127
Perrin, L. H., 783, 1497
Persico, T., 848
Persing, D. H., 409
Peruski, L., 796
Péter, O., 401
Peterkin, J., 1533
Peters, C. J., 277
Peters, G., 1023
Petersdorf, R. G., 1
Peterson, G., 320
Peterson, P. K., 260
Petrescu, M., 1339
Pettoello-Mantovani, M., 337

Phadnis, S. H., 812
Pham, B., 898
Philips, J. B., III, 790
Phillips, A. N., 331, 1521
Phillips, P., 252
Philpott, D. J., 955
Phuong, C. X. T., 778
Phuong, P. T., 778
Pi, T., 617, 625
Picard, B., 642
Pickering, L. K., 881
Piedra, P. A., 1394
Pieniazek, D., 227
Pieniazek, N. J., 227
Pietrella, D., 347
Pilkington, G. R., 1073
Pini, N., 529
Pinto Vaz, A. R. J. P. M., 1112
Pittman, P. R., 634
Plikaytis, B. D., 683
Plotkin, S. A., 1290
Plummer, F. A., 551
Podbielski, A., 991
Poggi, C., 235
Pollard, R. B., 48
Polonelli, L., 807
Poltoratskaia, N., 1138
Pomerantz, R. J., 1073
Ponce de Leon, A., 1107
Pope, V., 167
Porat, N., 1003
Posavad, C. M., 543
Powderly, W., 48
Power, M. E., 48
Prajgrod, F., 1003
Prammananan, T., 1573
Prince, A. M., 889
Proctor, R. A., 1023
Profizi, N., 235
Puhr, N., 1041
Pukkala, E., 1710
Purcell, R. H., 855
Purner, M. B., 746
Putvatana, R., 221
Qadri, F., 1594
Que, Y.-A., 146
Quinn, G. C., 1138
Quinn, J., 231
Quinn, T. C., 417, 1480
Quintó, L., 1409
Raboud, J., 1514
Racines, J., 1352
Radolf, J. D., 941
Rae, S., 1514
Raeder, R., 991
Ragazzoni, H., 1405
Ragnaud, J.-M., 1502
Rahn, K., 1139
Raker, C., 337
Ralston, M. L., 361
Ramachandran, S., 196
Ramirez, J. A., 1326
Ramirez, M., 707
Ramos, A., 227
Ramsburg, H. H., 634
Ran, L. J., 600
Ran, Z., 221
Rane, S., 1104
Rao, M., 796
Rasheed, S., 617, 625
Rathinam, C. R., 1314
Rayfield, M. A., 227
Read, R. C., 977
Rebiere, I., 155
Redd, S. B., 204
Redd, S. C., 204
Reed, J. B., 1182
Reed, S. G., 1339
Reed, S. L., 508
Regan, J. A., 790
Reichman, R., 617, 625
Reingold, A. L., 1104
Reneijer, L., 484
Remick, D. G., 1582
Renwick, S. A., 1139
Retini, C., 347
Revello, M. G., 1170
Rhoads, G. G., 790
Rice, D. H., 1588
Rice, T. W., 378
Richards, A., 1762
Richards, C. M., 1451
Richardson, B. A., 34
Richman, D. D., 40, 595
Ries, A. A., 962
Riester, K. A., 1480
Rigsby, M., 1715
Riley, L., 1480
Riley, L. W., 1138
Rinaldi, M. G., 425
Rittmann, M., 1405
Robbins, J. B., 383
Roberts, M. C., 677
Roblin, P. M., 720
Rochat, T., 1413
Rocourt, J., 155
Rodés, J., 839
Rogers, M., 1046
Rohrer, R., 459
Rokita, E., 803
Romeu, J., 1080
Rosenberg, H. F., 1458
Rosenberg, J., 161
Rosenqvist, E., 683
Rosenstein, I. J., 1386
Rosenthal, K. L., 1155
Ross, S. O., 320
Rosselet, A., 127
Rossi, C. A., 634
Rota, J. S., 204
Rota, P. A., 204
Rotbart, H. A., 1772
Roth, M., 793
Roth, R. I., 388
Rothenbacher, D., 1124
Rotter, M. L., 803
Rottmann, C., 1521
Roudot-Thoraval, F., 1541
Rouse, D., 1030
Rouzioux, C., 1737
Rowe, J. E., 529
Royce, R. A., 1742
Rudolph, D. L., 437, 1489
Ruiz, L., 1080
Ruiz, S., 1080
Russo, D. M., 1345
Russo, T. A., 97, 1120
Rutschmann, O. T., 783
Ryan, J. A., 1754
Saag, M. S., 40
Sabattini, M., 529
Sabin, C., 57
Sacks, D. L., 815
Sadoff, J. C., 1664
Saffer, D., 473
Safrin, S., 543
Safwat, M., 796
Saha, D., 1594
St. Jeor, S. C., 523, 529
St. Louis, M. E., 677
Sáiz, J.-C., 839
Sakamoto, M., 1475
Sakamoto, S., 1475
Saladino, R. A., 986
Salah, A. B., 1687
Salam, M. A., 1594
Salamat, M. S., 446
Salati, A., 807
Sällberg, M., 264
Salomon, N., 1138
Salpétrier, J., 1541
Salvat, G., 155
Sambhara, S., 1266
Sample, J. T., 1194, 1705
Sampoleo, R., 320
Samson, J., 1087
Sánchez, F. O., 133
Sánchez-Tapias, J.-M., 839
Sander, P., 1573
Sanders, C. C., 951
Sandstedt, B., 247
Sarasini, A., 1170
Sarfati, C., 1373
Sasso, D. R., 1489
Sattler, F. R., 48
Satz, N., 401
Sauerwein, R., 1358
Sauerwein, R. W., 1401
Savara, A., 1549
Savarino, M., 520
Savarino, S. J., 796
Sawhney, N., 238
Sayers, D., 677
Scalone, A., 1339
Schaller, M.-D., 127
Schalm, S. W., 1382
Schapiro, J. M., 477
Schechter, M., 227
Schiller, J., 1710
Schlech, W. F., III, 252
Schlegel-Haueter, S. E., 1413
Schlievert, P. M., 1773
Schluger, N., 1138
Schluger, R., 1533
Schmaljohn, A. L., 634
Schmid, I., 1083
Schmidt, R. E., 1723
Schnittman, S., 1730
Schochetman, G., 227
Schock, J. L., 1742
Schockmel, G. A., 1497
Scholl, D., 217
Schuchat, A., 998
Schuitemaker, H., 600
Schurr, E., 133
Schwartz, D. H., 301, 310, 1230
Scott, W., 617, 625
Sears, C. L., 754
Secka, O., 1758
Sellin, M., 967
Semba, R. D., 611
Semprini, A. E., 848
Senneville, E., 1776
Sépou, A., 1770
Seppälä, H., 786
Serafini, P., 848
Sermet, C., 492
Seroky, J. T., 1260
Shaffer, J. M., 1036
Shafran, S. D., 252
Shapiro, D. E., 557
Shapiro, M., 855
Shearer, M. H., 1727
Shenep, J. L., 766
Sherif, M., 1364
Sherman, P. M., 955
Shillington, A., 1514
Shimeld, C., 1451
Shirai, M., 72
Shlian, D. M., 1083
Shoemaker, C. B., 1364
Shougui, W., 221
Shoup, R. E., 1608
Siber, G. R., 986
Sierra, G., 683
Silber, E., 473
Siliciano, R., 1230
Sillos, E. M., 1046
Silva-Graça, A., 65
Simoes, E. A. F., 467
Simon, R. P., 931
Simoncini, L., 1170
Sinangil, F., 1230
Singer, J., 252
Sirera, G., 1080
Sirianni, M. C., 1715
Sixbey, J. W., 1194, 1705
Skamene, E., 133
Skeiky, Y. A. W., 1339
Skinhøj, P., 331, 1214
Skoner, D. P., 1260
Slutsker, L., 962, 1588
Small, P. M., 1104, 1107
Smeaton, L. M., 40
Smith, I. L., 565
Smith, J., 523

Smith, J. D., 977
Smith, K., 1696
Smulian, A. G., 238
Snow, R. W., 819
Snyder, G., 1046
Snydman, D. R., 425, 459
Sobel, J., 1405
Sohnle, P. G., 812
Sokol, K., 1563
Solomon, N., 1723
Sonigo, P., 1737
Sonnenberg, P., 473
Sorensen, S. J., 1608
Soriano, V., 65, 227, 1221
Sotolongo, F., 683
Sousa, A. O., 1554
Spaete, R. R., 1143
Speck, C. E., 320
Spector, F. C., 1143
Spector, S. A., 40, 565
Sperling, R. S., 557
Speth, C., 905
Spielman, A., 242
Spika, J., 1139
Spinola, S. M., 1608
Srinivas, S. K., 1705
Stablein, D., 301, 1230
Stack, A. M., 986
Stafford, M. K., 1386
Stainsby, C., 1097
Stapleton, A., 97
Staszewski, S., 1521
Staton, S., 1046
Steele, P. M., 1418
Steere, A. C., 401
Stein, A., 231
Steiner, T. S., 88
Sterneck, M., 1378
Stevens, R., 579
Stiles, B. G., 1013
Stilianakis, N. I., 863
Stoll, M., 1723
Stoute, J. A., 1664
Strady, A., 1290
Straus, S. E., 293
Strickman, D., 800
Strockbine, N., 1405
Studenberg, S., 1046
Su, B., 247
Su, D., 388
Subianto, B., 1762
Sucato, G., 1069
Sugar, A. M., 1660
Summersgill, J. T., 1326
Sun, E., 898
Sun, P.-f., 1664
Sun, R., 1715
Sun, W., 737
Sundar, S., 815
Surawicz, C., 571
Sutamihardia, M. A., 1762
Suter, S., 1413
Sutich, E. G., 1308
Sutton, D. A., 425
Sutton, L., 1549
Suzuki, H., 519
Suzuki, K., 284
Svennerholm, A.-M., 796
Swetter, S. M., 543
Switzer, W. M., 65
Szu, S. C., 383
Tacket, C. O., 662
Takabayashi, T., 1622
Takahashi, S., 1116
Takeda, Y., 3
Talkington, D. F., 161, 167
Tamaki, K., 284
Tamane, A., 1266
Tambe, P., 167
Tang, B., 455
Tang, H. B., 1480
Tanner, L. M., 401
Tanowitz, H. B., 515
Tanuri, A., 227
Tarantal, A. F., 446
Tarara, R. P., 1247
Tarr, P. I., 1774
Tartaglia, J., 1230
Täuber, M. G., 692
Tauxe, R. V., 1041, 1405
Taylor, G., 874
Taylor, G. P., 1097
Taylor-Robinson, D., 1386
Tchuinkam, T., 1358
Tebas, P., 217
Telford, S. R., III, 242, 395, 409, 737, 1422
ten Cate, J. W., 793
Thacker, W. L., 161
Thauvin, M., 1541
Theus, S. A., 238, 941
Thiers, V., 848
Thijs, L. G., 81
Thomas, D. L., 539, 1480
Thomas, L. H., 874
Thompson, C. M., 986
Thompson, R. W., 196
Thoresson, A.-C., 247
Thornton, A. C., 1608
Thuc, N. V., 133
Thuma, P. E., 1064
Thursz, M., 264
Tiemessen, C. T., 921
Tierno, P. M., Jr., 824
Tikhomirov, E., 683
Tillmann, H. L., 1723
Timanus, D. K., 1727
Tine, J. A., 1664
Tingle, A. J., 5
Tirén, U., 247
Toma, E., 252, 355
Tomasz, A., 707
Tomavo, S., 746
Tompkins, M. B., 18
Tompkins, R. G., 1622
Tompkins, W. A. F., 18
Toner, C., 107
Torelli, G., 520
Toresani, I. E., 1308
Torian, B. E., 508
Torre, N. D., 227
Torriani, F. J., 595, 1182
Tran, H. T., 383
Tran, V. Q., 508
Trautwein, C., 1723
Treml, J. F., 182
Tropea, M. M., 116
Tsai, T. F., 221
Tsenova, L., 1563
Tudor-Williams, G., 1097
Tuomanen, E., 766
Tural, C., 1080
Tureen, J. H., 692
Turgeon, F., 252
Tuveri, R., 848
Tyson, R. W., 1772
Uccini, S., 1715
Ueda, Y., 284
Uehling, D. T., 1296
Uhl, J. R., 409
Ullum, H., 331
Ulrich, R. G., 1013
Underdown, B., 1266
Valverde, C. R., 1247
van Binnendijk, R. S., 484
van Burik, J., 571, 1775
van der Laken, C. J., 1398
van der Meer, J. W. M., 175, 1398, 1401
van der Poll, T., 793
Van Dervort, A. L., 116
van Deuren, M., 1401
van de Ven, M. T. P., 1398
van Lieshout, L., 102
Vannier, E., 1622
Van Reeth, K., 1076
Van Rompay, K. K. A., 1247
van Schaik, S. M., 269
Van Voorhis, W. C., 1036
Vargas, I., 269
Vargas, M., 1409
Vauzelle-Kervroëdan, F., 492
Vecchiarelli, A., 347
Veit, P., 155
Venzon, D. J., 1207
Verjans, G. M. G. M., 484
Vermund, S. H., 310
Vernazza, P. L., 224, 1742
Vetrovec, G. W., 209
Viale, A. M., 1308
Viani, R. M., 565
Vicente, A. C. P., 227
Victor, J., 331
Vieira, J., 1069
Vierra, M., 477
Vila, J., 1409
Villano, S. A., 1480
Viscoli, C., 1775
Visser, J., 451
Vlahov, D., 539, 611
Voladri, R. K. R., 701
Völker-Dieben, H. J., 484
von Hofe, E., 523
von Laer, D., 1162
von Reyn, C. F., 730
Vugia, D. J., 161
Vuopio-Varkila, J., 786
Wages, J., Jr., 855
Wahl, S., 1214
Wainberg, M., 1730
Wainwright, N. R., 388
Wakabayashi, E., 1069
Waki, S., 1674
Wald, A., 1069, 1775
Wald, E. R., 504
Walker, M. C., 1230
Walker, S. J., 497
Wallace, R. J., Jr., 1573
Wallis, R. S., 1746
Walsh, E. E., 463
Walzer, P. D., 238
Wang, J. B., 209
Wang, Y., 293
Wang, Z., 1710
Wara, D., 470
Ward, H., 1386
Warhurst, D. C., 1429
Watanabe, T., 284
Watt, G., 800
Weber, J. N., 1097, 1386
Weber, J. T., 1041
Webster, A. D. B., 1719
Weigel, M. M., 1352
Weinhold, K., 301, 1230
Weinstein, R. A., 378
Weinstock, H. S., 931
Weintrub, P. S., 470
Weiser, J. N., 368
Weiskopf, E. E., 579
Weislow, O., 1730
Weisman, L. E., 790
Weiss, G., 1064
Weiss, L. M., 515
Weissman, D., 1332
Wellde, B. T., 1664
Welliver, R. C., 269
Wells, J. G., 962, 1041
Wenger, J. D., 683
Werner, E. R., 1064
Werner, S. B., 161
Wesley, R. A., 116
Westley, B., 1405
White, N. J., 778
White, S. A., 107
Whittam, T. S., 1774, 1750
Whittington, W. L., 677
Whittle, H. C., 256, 1282
Widjaja, H., 1762
Wierzba, T., 796
Wiktor, S., 65
Will, H., 1378
Willemsen, L., 1358
Williams, D., 683
Williams, D. E., 730
Williams, M., 1405
Williams, M. A., 107

Williams, N. A., 1451
Willinger, B., 803
Wilson, J. B., 1139
Wilson, R., 1774
Wiltshire, H., 337
Winters, M. A., 477
Wirtz, R. A., 1664
Withington, S., 107
Witkin, S. S., 714
Wittner, M., 515
Wizel, B., 1664
Wolbink, G.-J., 81
Wolff, A. G., 501
Wolff, M. C., 310
Wolinsky, S. M., 310
Wolitz, R. A., 1176
Women and Infants Transmission Study, 1480
Woods, S., 1266
Woody, M. A., 1013
Woolley, J. L., 1046
Wright, A., 1097
Wright, P. F., 310, 1230
Wuhib, T., 754
Würzner, R., 1057
Wyld, S. G., 874
Wyvill, K., 1506
Xia, M., 677
Xiao, L., 437
Xu, S., 1230
Yagupsky, P., 1003
Yamada, T., 1696
Yamamoto, S., 1221
Yang, Z., 1104
Yarchoan, R., 1506
Yashuk, J. C., 1041
Yasui, K., 1475
Yates, P. J., 265
Yazdanbakhsh, M., 1433
Yeh, K.-Y., 1202
Yeh, R. W., 1107
Yerly, S., 1497
Yin, T., 1682
Yoneto, T., 1674
Yong, K. L., 1465
Yong-Xin, Y., 221
Yoshimoto, T., 1674
Youle, M., 48
Young, L. S., 1449
Yousef, O., 1696
Youssef, F., 796
Yu, V. L., 425
Yu, Y. C., 425
Yuan, H., 1682
Yuen, G. J., 1533
Yun, A. J., 855
Yurasov, S., 337
Zackin, R., 761
Zaidi, A. A., 167
Zarowny, D. P., 252
Zavattoni, M., 1170
Zerboni, L., 1701
Zhang, S., 1682
Zhang, Y., 1573
Zhu, G., 1443
Zimba, D., 1742
Zolla-Pazner, S., 889, 1230
Zuckier, L., 1647

# Subject Index


ABO blood types, urinary tract infections and, 1296
Abscess, *Staphylococcus aureus*, guinea pig model, 701
*N*-Acetylmuramyl-L-alanine amidase, in body fluids, in bacterial meningitis, 102
Acquired immunodeficiency syndrome (*See* Human immunodeficiency virus infection)
Activator protein-1, in interleukin-8 production, in respiratory syncytial virus infections, 1275
Acute-phase response
  interleukin-6 in, complement regulation, 1622
  in osteomyelitis, 1582
Acyclovir
  prophylactic, for cytomegalovirus infections, in HIV infection, 48
  resistance to, herpes simplex virus, 217, 543
Adenovirus infections, in liver transplantation, 459
Adhesion, *Streptococcus pneumoniae*, to neutrophils, 977
Adhesion molecules, in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 107
*aer* gene, *Escherichia coli*, uropathogenic, 1120
Agammaglobulinemia, X-linked, GB virus C infection in, 1719
AIDS (*See* Human immunodeficiency virus infection)
AIDS dementia complex, meningitis in, 473
Albendazole, for microsporidiosis, in HIV infection, 1373
Alphaviruses, vaccination, 634
Alveolar cells
  phospholipid secretion by, *Pneumocystis carinii* glycoprotein A inhibition, 182
  *Streptococcus pneumoniae* adhesion to, 977
Amikacin, resistance to, mycobacteria, 1573
Aminoglycosides, resistance to, mycobacteria, 1573
Aminoguanidine, neonatal meningitis exacerbation by, rat model, 692
Amphotericin B
  for *Candida albicans* infections, itraconazole interactions with, mouse model, 1660
  for *Candida* fungemia, 425
  lipid complex, for visceral leishmaniasis, 815
Ampicillin, prophylactic, in wound infections, *Staphylococcus aureus*, guinea pig model, 701
Amplification assays, for *Streptococcus agalactiae* genomic diversity, 1308
Anal canal
  cancer, in human papillomavirus infections, in homosexual men, 361
  HIV in, in homosexual men, 571
Anemia
  in ehrlichiosis, mouse model, 737
  in parvovirus B19 infections, in HIV infection, 1773
Animal models
  *Bartonella* infections, with tickborne organisms, mouse, 409
  *Borrelia burgdorferi* immune evasion, tickborne vs. host-adapted, mouse, 395
  *Candida albicans* infections, granulocyte colony-stimulating factor in, mouse, 175
  candidiasis treatment, mouse, 1660
  *Chlamydia pneumoniae* dissemination, mouse, 1322
  *Cryptococcus neoformans* capsular polysaccharide, immune mechanism
    effects on, 1647
cytomegalovirus infections
  mouse, 523
  neurologic disease, rhesus monkey, 446
ehrlichiosis transmission, mouse, 1422
endotoxemia
  *Limulus* antilipopolysaccharide factor in, mouse, 388
  nitric oxide synthase inhibition in, mouse, 127
  treatment with doxycycline, mouse, 489
enterovirus infections, mouse, 1772
eosinophilic pneumonia, in cryptococcosis, mouse, 1639
granulocytic ehrlichiosis, mouse, 737
*Helicobacter pylori* infections, with HIV infection, mouse, 72
hepatitis G, chimpanzee, 855
herpes simplex virus type 1 mucosal immune response, mouse, 1451
herpes simplex virus vaccination
  guinea pig, 1143
  mouse, 1155
human immunodeficiency virus infection
  cat (feline immunodeficiency virus), 18
  cytokine expression in, macaque (simian immunodeficiency virus), 26
  multidrug therapy, mouse, 337
  vaccination
    mouse, 889
    rhesus macaque (simian immunodeficiency virus), 1247, 1771
influenza, pig, 1076
interleukin-1 receptors in inflammation, mouse, 1398
leishmaniasis, mouse, 188
Lyme carditis, mouse, 242
malaria resistance, mouse, 1674
meningitis
  mycobacterial, rabbit, 1563
  neonatal, rat, 692
  tuberculous, rabbit, 1563
methicillin-resistant *Staphylococcus aureus*, rat, 146
microsporidiosis, mouse, 515
peritonitis, gram-negative, rabbit, 668
pneumococcal anticapsular antibodies, rat, 986
*Pneumocystis carinii* pneumonia, rat, 1046
respiratory syncytial virus infection
  mouse, 269
  vaccination, bovine, 874
rotavirus diarrhea pathogenesis, mouse, 455
*Staphylococcus aureus* vaccination, mouse, 1013
streptococci group A virulence factors, mouse, 991
*Streptococcus pneumoniae* infections, mouse, 368, 707
*Trypanosoma cruzi trans*-sialidase, mouse, 431
tuberculosis pathogenesis, mouse and guinea pig, 1030
uveitis, varicella-zoster virus, guinea pig, 293
wound infections, *Staphylococcus aureus*, guinea pig, 701
Anorectal infections
  cancer, in human papillomavirus infections, in homosexual men, 361
  HIV in, in homosexual men, 571
Antibiotics (*See also specific antibiotics*)
  in *Escherichia coli* culture, endotoxin levels and, 1302
  prophylactic (*See* Prophylaxis)
  resistance to (*See* Drug resistance)
  susceptibility testing (*See* Susceptibility testing)
  usage trends, France, 492
Antibody(ies)
  avidity
    in *Haemophilus influenzae* vaccine evaluation, 1112
    in *Streptococcus pneumoniae* vaccine evaluation, 1614
  candidacidal, mycobactericidal activity, 807

capsular polysaccharide, in eosinophilic pneumonia, in cryptococcosis, mouse model, 1639
*Chlamydia pneumoniae*, in respiratory infections, 720
chlamydial heat-shock protein, scarring trachoma and, 256
colonization factor antigens, in enterotoxigenic *Escherichia coli* diarrhea prophylaxis, 662
deficiencies, GB virus C infection in, 1719
GB virus C, in intravenous drug users, 539
gp160 envelope protein, high maternal titer, transmission enhancement in, 1737
heat-shock proteins, in pelvic inflammatory disease, *Chlamydia trachomatis*, 714
human herpesvirus 8, in relatives of Kaposi's sarcoma patients, 1715
human papillomavirus, stability over time, 1710
monoclonal (*See* Monoclonal antibody)
neutralizing
in HIV vaccination, 301, 889
for respiratory syncytial virus infections, 1073
*Orientia tsutsugamushi*, dot blot immunoassay for, 800
*Plasmodium vivax*, 1132
pneumococcal anticapsular, rat model, 986
rabies, persistence after vaccination, 1290
respiratory syncytial virus, in elderly persons, 463
*Streptococcus pneumoniae*, after vaccination, 1614
toxin-like, mycobactericidal activity, 807
*Vibrio cholerae*, in endemic region, 1594
Antigens
colonization factor, milk antibody to, in enterotoxigenic *Escherichia coli* diarrhea prophylaxis, 662
*Escherichia coli*, 1774
hantavirus, tissue distribution, 1696
hepatitis B virus, mutations, 264
human immunodeficiency virus, fungal immunity and, 347
*Leishmania chagasi*, in leishmaniasis monitoring, in HIV infection, 1339
Lewis, urinary tract infections and, 1296
major histocompatibility complex, down-regulation, varicella-zoster virus in, 1390
malaria, persistent humoral immune response to, 1132
measles virus, cytotoxic T cell response to, human leukocyte antigens and, 1282
molluscum contagiosum virus, 284
*Mycobacterium tuberculosis*, in HIV replication, 1332
*Pneumocystis carinii*, T lymphocyte response to, in HIV infection, 238
*Schistosoma*, immune response to, 1364, 1433
*Strongyloides stercoralis*, in strongyloidiasis diagnosis, 196
*Toxoplasma gondii*, as superantigens, 746
Antilipopolysaccharide factor, *Limulus*, for endotoxemia, mouse model, 388
Antimony compounds, for visceral leishmaniasis, 815
Antiretroviral agents (*See also specific drugs*)
for HIV infection, assessment with viral RNA levels, 40
Antiviral agents (*See specific drugs*)
Argentine hemorrhagic fever, vaccination, 277
$N^G$-γ-L-Arginine methyl ester, in nitric oxide synthase inhibition, mouse model, 127
Artemisinin, resistance to, *Toxoplasma gondii*, 1128
Arthritis, in rubella vaccination, human leukocyte antigen associations with, 5
Aspergillosis, prevention, in bone marrow transplantation, 1775
Atherosclerosis
coronary artery, cytomegalovirus infections and, 209
pathogenesis, *Chlamydia pneumoniae* in, 725
Atovaquone, for *Pneumocystis carinii* pneumonia, rat model, 1046
Avidity, antibody
in *Haemophilus influenzae* vaccine evaluation, 1112
to *Streptococcus pneumoniae*, after vaccination, 1614
Azithromycin
for *Haemophilus ducreyi* infections, 1608
for *Mycobacterium avium* complex bacteremia, in HIV infection, 914
for *Mycoplasma pneumoniae* pneumonia prophylaxis, 161
AZT (*See* Zidovudine)

B cells
cytokine production in, in HIV infection, 905
hepatitis B virus core antigen sites, 264
JC virus latency in, in HIV infection, 1502
response
to schistosomiasis, 1364
to simian immunodeficiency virus vaccination, 26
*Babesia microti*, *Bartonella* and *Borrelia burgdorferi* with, mouse model, 409
Bacteremia
*Campylobacter*, in HIV infection, quinolone-resistant, 951
*Escherichia coli*, *papG* gene clonal distribution in, 651
*Mycobacterium avium* complex
in HIV infection, 1746
treatment, 914
viral replication in, 595
treatment with rifabutin, uveitis in, 252
*Streptococcus pneumoniae*, rat model, 986
Bangkok conference on emerging infections, 3
*Bartonella*, with tickborne organisms, mouse model, 409
Bejel, differentiation from other treponemal diseases, 1036
Biofilm, *Staphylococcus epidermidis*, salicylic acid–mediated inhibition, 501
Biopterin, in cerebrospinal fluid, in cerebral malaria, 1064
Blood
bacteria in (*See* Bacteremia)
HIV RNA in, vs. semen, 320
Bone infections, acute-phase response in, 1582
Bone marrow
examination, in parvovirus B19 infections, in HIV infection, 1773
transplantation
aspergillosis prevention in, 1775
cytomegalovirus monitoring after, 519
*Borrelia burgdorferi* (*See also* Lyme disease)
*Babesia microti* and *Bartonella* with, mouse model, 409
immune evasion by, tickborne vs. host-adapted, mouse model, 395
Bovine colostrum, in *Helicobacter* lipid receptor binding inhibition, 955
Brain, cytomegalovirus infection, rhesus monkey model, 446
Brainerd diarrhea, outbreak, Galapagos Islands, 1041
Breast milk, human immunodeficiency virus in, 34, 1770
Bronchiolitis, Simkania Z, in pediatric patients, 1425
Bronchoalveolar lavage fluid, cytokines in, in influenza, pig model, 1076
Bronchopulmonary dysplasia, respiratory syncytial virus vaccination in, 467
Burkitt's lymphoma cell line, Epstein-Barr virus reactivation in, viral episome loss in, 1705

Calprotectin, antimicrobial activity, 812
*Campylobacter*, bacteremia, in HIV infection, quinolone-resistant, 951
*Campylobacter fetus*, resistance in, quinolones, 951
Canarypox, in HIV vaccine preparation, 1230
Canavanine, in nitric oxide synthase inhibition, mouse model, 127
Cancer, anal, in human papillomavirus infections, in homosexual men, 361
Candid 1 vaccine, for Argentine hemorrhagic fever, 277

*Candida*, fungemia, treatment with amphotericin B, 425
*Candida albicans*
calprotectin activity against, 812
infections
disseminated, granulocyte colony-stimulating factor for, mouse model, 175
in HIV infection, envelope protein gp120 and, 347
treatment, mouse model, 1660
inflammation from, interleukin-1 receptors in, mouse model, 1398
virulence factors, HIV antigens as, 1057
Candidacidal antibodies, mycobactericidal activity, 807
Capsular polysaccharide
*Cryptococcus neoformans*
antibody to, in eosinophilic pneumonia, mouse model, 1639
immune mechanism effects on, mouse model, 1647
streptococci group B, in neonates, 790
*Streptococcus pneumoniae*, virulence and, mouse model, 368
Capsular transformation, *Streptococcus pneumoniae*, mouse model, 707
Carditis, Lyme, mouse model, 242
Carriage, oropharyngeal, *Haemophilus influenzae*, after vaccination, 1758
Catalase-peroxidase, in tuberculosis pathogenesis, mouse and guinea pig models, 1030
Cauliflower mosaic virus, as surrogate marker, for pathogen transmission, 881
CCR5 (chemokine receptor 5), heterozygosity for, HIV syncytium-inducing phenotype and, 1549
CD4 cells (*See* T cells, CD4)
CD11c molecule, in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 107
Cefamandole
prophylactic, for *Staphylococcus aureus* endocarditis, rat model, 146
resistance to, *Staphylococcus aureus*, rat model, 146
Cefazolin, prophylactic, for *Staphylococcus aureus* wound infections, guinea pig model, 701
Ceftazidime, in *Escherichia coli* culture, endotoxin and cytokine levels and, 1302
Cellular immune response (*See also* T cells)
to cholera, in endemic region, 1594
in ritonavir-saquinavir therapy, for HIV infection, 898
to schistosomiasis, 1364, 1433
to varicella vaccine, 1701
Central nervous system, lymphoma, human herpesvirus 8 in, 520
Cerebral malaria, cerebrospinal fluid analysis in, 1064
Cerebrospinal fluid
HIV RNA in, in meningitis, 473
matrix metalloproteinases in, in Lyme disease, 401
peptidoglycan-degrading enzymes in, in bacterial meningitis, 102
Cervix
CD4 lymphocytes in, in sexually transmitted diseases, 167
HIV load in, 1214
Chagas' disease, *Trypanosoma cruzi trans*-sialidase in, mouse model, 431
Chancroid, prophylaxis, 1608
Chemoattractants, in cytomegalovirus dissemination, 1465
Chemokine receptor 5 (CCR5), heterozygosity for, HIV syncytium-inducing phenotype and, 1549
$\beta$-Chemokines
in herpes simplex virus infections, recurrent, 827
HIV progression and, 331
Chemokines, in cytomegalovirus dissemination, 1465
Chemotactic factors, in bronchial secretions, in cystic fibrosis, 1413
Chemotaxis
cryptococcal glucuronoxylomannan effects on, 260
nitric oxide effects on, 116
Chickenpox, uveitis, guinea pig model, 293
Chikungunya virus, vaccination, 634
Child care settings, pathogen transmission in, surrogate markers for, 881
Children (*See* Pediatric patients)
*Chlamydia pneumoniae*
dissemination, mouse model, 1322
in foam cell formation, 725
replication, inhibition, 1326
respiratory infections, antibody response in, 720
*Chlamydia trachomatis*
pelvic inflammatory disease, immune response in, 714
trachoma, heat-shock proteins in, 256
in urine, molecular amplification assays for, 417
Chlamydial infections
cytomegalovirus seroconversion and, 1188
endocervical CD4 lymphocytes in, 167
treatment, organism persistence after, urine testing for, 417
Chloroquine, in malaria prophylaxis, tetanus-diphtheria vaccination during, 1762
Chlorproguanil, resistance to, *Plasmodium falciparum*, 1429
Cholera, immune response in, in endemic region, 1594
Cholera toxin subunit, in enterotoxigenic *Escherichia coli* vaccine preparation, 796
Chronic fatigue syndrome, T lymphocyte function in, 451
Ciprofloxacin
for *Haemophilus ducreyi* infections, 1608
resistance to, gonococci, 677
Clarithromycin, for *Mycobacterium avium* complex bacteremia, with rifabutin, 252
*cnf* gene, *Escherichia coli*, uropathogenic, 1120
Coagulation disorders, in parenteral nutrition, in endotoxemia, 793
Colonization
enterococci, vancomycin-resistant, 368
*Escherichia coli*
uropathogenic, 1120
verocytotoxigenic, in dairy farm families, 1139
*Helicobacter pylori*, in pediatric patients, 247
*Streptococcus pneumoniae*, drug-resistant, 1003
vaginal, microbicidal agent effects on, 1386
Colonization factor antigens, milk antibody to, in enterotoxigenic *Escherichia coli* diarrhea prophylaxis, 662
Colostrum
bovine, in *Helicobacter* lipid receptor binding inhibition, 955
human immunodeficiency virus in, 34
Common variable immunodeficiency, GB virus C infection in, 1719
Complement
activation, in sepsis, C-reactive protein in, 81
C5a, in neutrophil stimulation, cyclic guanosine monophosphate response to, 116
in interleukin-6 synthesis, 1622
Cornea, T cells in, in herpes simplex virus keratitis, 484
Coronary artery atherosclerosis, cytomegalovirus infections and, 209
C-reactive protein, in complement activation, in sepsis, 81
*Cryptococcus neoformans*
capsular polysaccharide, immune mechanism effects on, mouse model, 1647
infections, in HIV infection, envelope protein gp120 and, 347
meningitis
glucuronoxylomannan actions in, 260
in HIV infection, 473
pneumonia, mouse model, 1639
Cryptosporidiosis, epidemiology, Brazil, 754
*Cryptosporidium parvum*, detection, polymerase chain reaction in, 1443

Cutaneous leishmaniasis
progression, immunologic determinants, 1687
vaccination, 1352
C-X-C chemokines, in cytomegalovirus dissemination, 1465
Cyclic guanosine monophosphate, formation, in neutrophils, nitric oxide effects on, 116
Cystic fibrosis
bronchial secretions in, chemotactic factors in, 1413
*Staphylococcus aureus* infections in, 1023
Cystitis, *Escherichia coli*, *papG* gene alleles in, 97
Cytokines (*See also specific cytokines*)
in bacteremia, *Mycobacterium avium* complex, in HIV infection, 1746
in dengue hemorrhagic fever, 778
in *Escherichia coli* culture, vs. endotoxin release, 1302
in herpes simplex virus infections, recurrent, 827
in HIV infection, 905
in HIV replication, in tuberculosis, 1332
in mycobacterial infections, HIV infection effects on, 1554
peptidoglycan activation, 1629
in *Pneumocystis carinii* infections, in HIV infection, 238
in simian immunodeficiency virus infection, 26
in streptococcal group B infections, lactic acid effects on, 1418
in visceral leishmaniasis, 815
Cytomegalovirus
dissemination, 1465
glycoprotein B, genotypes, 1162
infections
in bone marrow transplantation, monitoring for, 519
coronary artery atherosclerosis and, 209
in HIV infection
prophylaxis with valaciclovir, 48, 57
viral DNA measurement in, 355
mouse model, 523
neurologic disease in, rhesus monkey model, 446
pathogenesis, 1465
in pregnancy, 1170
seroconversion, genital tract infections and, 1188
in nasal secretions and saliva, 213
resistance in, ganciclovir, 770, 1176
retinitis
ganciclovir resistance in, 770
in HIV infection, remission, 1080, 1182
susceptibility testing, 823
Cytotoxic T cells (*See* T cells, cytotoxic; T cells, CD8)

Dapsone, resistance to, *Plasmodium falciparum*, 1429
ddC (*See* Zalcitabine)
ddI (*See* Didanosine)
Degenerate oligonucleotide-primed amplification assay, for *Streptococcus agalactiae* genomic diversity, 1308
Dengue hemorrhagic fever, pathophysiology, cytokines in, 778
Dexamethasone, sensitivity to, in chronic fatigue syndrome, 451
Dextrin sulfate, vaginal flora alterations from, 1386
Diarrhea
Brainerd, outbreak, Galapagos Islands, 1041
*Cryptosporidium*, epidemiology, Brazil, 754
*Escherichia coli*
enteroaggregative, intestinal inflammation in, 88
enterotoxigenic, vaccination, 796
O157:H7
foodborne outbreak, 1588
risk factors for, 962
in microsporidiosis, treatment with TNP-470, mouse model, 515
rotavirus
epidemiology (1993–1995), 13
pathogenesis, mouse model, 455
transmission, in child care setting, surrogate markers for, 881
travelers'
enteroaggregative *Escherichia coli*, 1409
outbreak, Galapagos Islands, 1041
prophylaxis, 662
*Vibrio cholerae*, immune response in, 1594
Didanosine, for HIV infection
assessment with viral RNA levels, 40
resistance to, 1207, 1506, 1730
virus load measurement in, 1497
virologic marker changes in, 625
Dideoxycytidine (*See* Zalcitabine)
Dideoxynucleosides, resistance to, HIV, 1506
Dihydrofolate reductase, *Plasmodium falciparum*, drug resistance and, 1429
Dihydropteroate synthetase, *Plasmodium falciparum*, drug resistance and, 1429
Diphtheria-tetanus vaccination, during malaria prophylaxis, 1762
Dipstick assay, for *Orientia tsutsugamushi*, 800
DNA analysis
for *Plasmodium vivax* infection relapses, 511
for *Streptococcus agalactiae* genomic diversity, 1308
for strongyloidiasis, 196
DNA polymerase, hepatitis B virus, mutations, in lamivudine therapy, 1382
Docusate sodium, vaginal flora alterations from, 1386
Dot blot immunoassays, for *Orientia tsutsugamushi*, 800
Doxycycline, for endotoxemia, mouse model, 489
Drug abuse
GB virus C infection in, antibodies in, 539
HIV infection in, vitamin A supplementation in, 611
Drug resistance
acyclovir, herpes simplex virus, 217, 543
amikacin, mycobacteria, 1573
aminoglycosides, mycobacteria, 1573
artemisinin, *Toxoplasma gondii*, 1128
*Campylobacter fetus*, quinolones, 951
cefamandole, *Staphylococcus aureus*, rat model, 146
chlorproguanil, *Plasmodium falciparum*, 1429
ciprofloxacin, gonococci, 677
cytomegalovirus, ganciclovir, 770, 1176
dapsone, *Plasmodium falciparum*, 1429
didanosine, human immunodeficiency virus, 1207, 1506, 1730
dideoxynucleosides, 1506
enterococci, vancomycin, genotyping, 368
erythromycin, streptococci group A, 786
*Escherichia coli*, 1774
fluoroquinolones, gonococci, 677
ganciclovir, cytomegalovirus, 770, 1176
gentamicin, mycobacteria, 1573
gonococci, fluoroquinolones, 677
hepatitis B virus, lamivudine, 1382
herpes simplex virus
acyclovir, 543
screening for, 217
human immunodeficiency virus, 1506
didanosine, 1207, 1506, 1730
dual, 1521
multiple, 1207
saquinavir, 477
zidovudine, 557, 1207, 1730
influenza virus, 863
kanamycin, mycobacteria, 1573

lamivudine
hepatitis B virus, 1382
human immunodeficiency virus, 1521
malaria, 1429
multiple
human immunodeficiency virus, 1506
*Streptococcus pneumoniae*, 1003
mouse model, 707
tuberculosis, 1138
*Mycobacterium abscessus*, aminoglycosides, 1573
*Mycobacterium chelonae*, aminoglycosides, 1573
*Neisseria gonorrhoeae*, fluoroquinolones, 677
neomycin, mycobacteria, 1573
*Plasmodium falciparum*, 1429
pyrimethamine, *Plasmodium falciparum*, 1429
quinolones, *Campylobacter fetus*, 951
streptococci group A, erythromycin, 786
*Streptococcus pneumoniae*, 1003
mouse model, 707
sulfadoxine, *Plasmodium falciparum*, 1429
tobramycin, mycobacteria, 1573
*Toxoplasma gondii*, artemisinin, 1128
vancomycin, enterococci, genotyping, 368
zalcitabine, HIV, 1207, 1506
zidovudine, 557, 1207, 1521, 1730

Ear infections, in influenza, rimantadine effects on, 1260
Ehrlichiosis
pathogenesis, mouse model, 737
transmission, tick attachment duration for, mouse model, 1422
Elderly persons, respiratory syncytial virus antibodies in, 463
Electrophoresis
field inversion gel, for group A streptococci typing, 504
pulsed-field gel, for *Shigella sonnei* identification, 1405
Emerging infections, international conference on, 3
*emm* gene, streptococci group A, virulence and, mouse model, 991
Encephalitis
herpes simplex virus, vaccination for, mouse model, 1451
Japanese encephalitis virus, vaccination, 221
*Encephalitozoon cuniculi*, infections, treatment with TNP-470, mouse model, 515
*Encephalitozoon intestinalis*, infections, in HIV infection, treatment, 1373
Endocarditis
*Staphylococcus aureus*, methicillin-resistant, prophylaxis, rat model, 146
streptococci group B, IS1548 insertion element in, 967
Endothelial cells
cytomegalovirus-infected, neutrophil recruitment by, 1465
peptidoglycan action on, 1629
Endothelium-derived relaxation factor (*See* Nitric oxide)
Endotoxemia
*Limulus* antilipopolysaccharide factor in, mouse model, 388
nitric oxide synthase inhibition in, mouse model, 127
parenteral nutrition in, coagulation in, 793
treatment with doxycycline, mouse model, 489
*Entamoeba histolytica*, virulence factors, neutral cysteine proteinase, 508
Enterococci, resistance, vancomycin, genotyping, 368
Enterotoxin, NSP4 protein as, in rotavirus diarrhea pathogenesis, mouse model, 455
Enterotoxin B, staphylococcal, modified, in vaccine development, mouse model, 1013
Enterovirus, infections, mouse model, 1772
Eosinophil(s), neurotoxin/RNase 2 derived from, for respiratory syncytial virus infections, 1458
Eosinophilic pneumonia, in cryptococcosis, mouse model, 1639
Epidemiology (*See also* Outbreaks)
cryptosporidiosis, Brazil, 754
gonococcal resistance, 677
hantaviruses, Argentina, 529
herpes simplex virus type 2 seropositivity, in HIV infection, Zimbabwe, 481
human herpesvirus 8 variants, Brazil, 1136
human papillomavirus infections, in homosexual men, 361
influenza, drug resistance, 863
listeriosis, France, 155
measles, genetic analysis (1995–1996), 204
meningococcal infections, New Zealand, 497
*Mycobacterium tuberculosis*, San Francisco, 1104
*Neisseria meningitidis*, serogroup B, electrophoretic type 15, Canada, 1754
neurosyphilis, in HIV infection, San Francisco, 931
rotavirus diarrhea hospitalizations (1993–1995), 13
*Shigella sonnei* infections, in traditionally observant Jewish communities, 1405
streptococci group A
invasive, 1773
resistance in, Finland, 786
travelers' diarrhea, Galapagos Islands, 1041
tuberculosis, San Francisco, 1104
Epithelial cells, peptidoglycan action on, 1629
Epstein-Barr virus
infections
vs. HIV infection, CD8 subsets in, 1083
in HIV infection, in pediatric patients, 1087
reactivation, viral episome loss in, 1705
latent, eradication, 1194
in nasal secretions and saliva, 213
Equine encephalitis virus, Venezuelan, vaccination, 634
Errata, cytomegalovirus drug resistance (176:69-77), 1140
Erythrocytes, types of, urinary tract infections and, 1296
Erythromycin, resistance to, streptococci group A, 786
*Escherichia coli*
bacteremia, *papG* gene clonal distribution in, 651
culture, antibiotic-treated, endotoxin and cytokine levels in, 1302
cystitis, *papG* gene alleles in, 97
enteroaggregative
diarrhea, intestinal inflammation in, 88
travelers' diarrhea, 1409
enterotoxigenic
diarrhea, prophylaxis, 662
vaccination, 796
$\beta$-galactosidase, insertion into varicella-zoster virus, guinea pig model, 293
inflammation from, interleukin-1 receptors in, mouse model, 1398
meningitis, phylogenetic analysis, in neonates, 642
O antigen, 1774
O157, vaccination, 383
O157:H7
diarrhea, foodborne outbreak, 1588
evolutionary emergence, 1750
infections, risk factors for, 962
virulence factors, 1750
peritonitis, rabbit model, 668
resistance in, 1774
uropathogenic, colonization, 1120
verocytotoxigenic, in dairy farm families, 1139
virulence factors, 642
uropathogenic, 1120

Ethambutol, for *Mycobacterium avium* complex bacteremia, with rifabutin, 252
Eye infections
herpes simplex virus
corneal T cells in, 484
vaccination for, mouse model, 1451
*Leptospira*, polymerase chain reaction in, 1314
trachoma, chlamydial heat-shock proteins and, 256
varicella-zoster virus, guinea pig model, 293

Fab RSVF2-5 monoclonal antibody, for respiratory syncytial virus infections, 1073
Fc receptors, expression, in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 107
Feline immunodeficiency virus, immune response to, 18
Field inversion gel electrophoresis, for group A streptococci typing, 504
Fluoroquinolones, resistance to, gonococci, 677
FMLP, in neutrophil stimulation, cyclic guanosine monophosphate response to, 116
Foam cells, formation, *Chlamydia pneumoniae* in, 725
Foodborne diseases
Brainerd diarrhea, 1041
*Escherichia coli* O157:H7 infections, 1588
risk factors for, 962
listeriosis, epidemiology, France, 155
Fumagillin analogue (TNP-470), for microsporidiosis, mouse model, 515
Fungal infections (*See also specific infections*)
in HIV infection, envelope protein gp120 action in, 347
Fungemia, *Candida*, treatment with amphotericin B, 425

$\beta$-Galactosidase, *Escherichia coli*, insertion into varicella-zoster virus, guinea pig model, 293
Gametocyte carriers, *Plasmodium falciparum*, immune response in, 1358
Ganciclovir
for cytomegalovirus infections, mouse model, 523
for leishmaniasis, mouse model, 188
resistance to, cytomegalovirus, 770, 1176
Gangliotetraosylceramide, *Helicobacter* binding to, bovine colostrum effects on, 955
Gangliotriosylceramide, *Helicobacter* binding to, bovine colostrum effects on, 955
Gastritis, *Helicobacter pylori*, virulence factors, in pediatric patients, 247
GB virus C (hepatitis G virus)
absence, in semen, 848
genetic analysis, chimpanzee model, 855
infections
antibodies in, in intravenous drug users, 539
in HIV infection, 1723
in primary antibody deficiency, 1719
transmission, vertical, 1202
Gel electrophoresis
field inversion, for group A streptococci typing, 504
pulsed-field, for *Shigella sonnei* identification, 1405
Genital herpes infections
acyclovir-resistant, 543
epidemiology, in HIV infection, Zimbabwe, 481
latent, 1069
recurrent, 1069
vaccination
guinea pig model, 1143
mouse model, 1155
Genital tract infections, cytomegalovirus seroconversion and, 1188
Genital ulcer disease
*Haemophilus ducreyi*, prophylaxis, 1608
herpes simplex virus, acyclovir-resistant, 543
in HIV infection, 481
viral RNA in, 224
Gentamicin, resistance to, mycobacteria, 1573
Glucuronoxylomannan, *Cryptococcus neoformans*
actions, 260
immune mechanism effects on, mouse model, 1647
Glycoprotein, *Pneumocystis carinii*, T lymphocyte response to, in HIV infection, 238
Glycoprotein A, *Pneumocystis carinii*, in surfactant inhibition, 182
Glycoprotein B, cytomegalovirus, genotypes, 1162
Gonococci, resistance in, epidemiology, 677
Gonorrhea
cytomegalovirus seroconversion and, 1188
endocervical CD4 lymphocytes in, 167
repeated, risk factors for, San Francisco, 1766
gp41 envelope protein, human immunodeficiency virus
as *Candida albicans* virulence factor, 1057
cytokine production and, 905
gp120 protein, human immunodeficiency virus
fungal immunity and, 347
in vaccine preparation, 1230
gp160 envelope protein, human immunodeficiency virus
as *Candida albicans* virulence factor, 1057
high antibody titer, transmission enhancement in, 1737
Gram-negative peritonitis, rabbit model, 668
Granulocyte(s), *Helicobacter pylori* urease stimulation, 803
Granulocyte colony-stimulating factor
for *Candida albicans* infections, mouse model, 175
for HIV infection, 1733
Granulocyte-macrophage colony-stimulating factor
for *Mycobacterium avium* complex bacteremia, in HIV infection, 914
for sepsis, 107
Granulocytic ehrlichiosis
pathogenesis, mouse model, 737
transmission, tick attachment duration for, mouse model, 1422
GRO$\alpha$, in cytomegalovirus dissemination, 1465

*Haemophilus ducreyi*, infections, prophylaxis, 1608
*Haemophilus influenzae*, vaccination, 1112
oropharyngeal carriage and, 1758
Hamburger, *Escherichia coli* O157:H7 infections from, 962
Hantaviruses
antigens, tissue distribution, 1696
epidemiology, Argentina, 529
genetic diversity, Argentina, 529
Heat-shock proteins
chlamydial, scarring trachoma and, 256
in pelvic inflammatory disease, *Chlamydia trachomatis*, 714
*Helicobacter mustelae*, lipid receptor binding inhibition, by bovine colostrum concentrate, 955
*Helicobacter pylori*
colonization, in pediatric patients, 247
infections
with HIV infection, mouse model, 72
peptic ulcer disease in, 1124
lipid receptor binding inhibition, by bovine colostrum concentrate, 955
urease, in phagocytosis, 803
virulence factors, in pediatric patients, 247
Helper T cells (*See* T cells, CD4)
Hemagglutinin-neuraminidase gene nucleotide sequence, mumps virus vaccine strain, 265
Hemolysin, in *Escherichia coli* cystitis, 97
Hemorrhagic fever

Argentine, vaccination, 277
dengue, pathophysiology, cytokines in, 778
Hepatitis B virus
antigens, mutations, 264
B cell recognition sites, 264
infections, fulminant, in neonates, 1378
resistance in, lamivudine, 1382
transmission, vertical, 1378
Hepatitis C virus
absence, in semen, 848
infections
in HIV infection, protease inhibitor effects on, 783
viral dynamics, interferon-$\alpha$ effects on, 1475
nonstructural 5A gene interferon sensitivity determining region, 839
transmission, perinatal, in HIV infection, 1480
Hepatitis G virus (GB virus C)
absence, in semen, 848
genetic analysis, chimpanzee model, 855
infections
antibodies in, in intravenous drug users, 539
in HIV infection, 1723
in primary antibody deficiency, 1719
transmission, vertical, 1202
Herpes simplex virus
infections, recurrent, cytokine production in, 827
keratitis, corneal T cells in, 484
resistance in
acyclovir, 543
screening for, 217
type 1
genital infections, latency, 1069
latency, mouse model, 1451
mucosal immune response to, mouse model, 1451
type 2
genital infections
acyclovir-resistant, 543
epidemiology, in HIV infection, Zimbabwe, 481
latent, 1069
vaccination
guinea pig model, 1143
mouse model, 1155
Herpes zoster
uveitis, guinea pig model, 293
vaccination for, mouse model, 1451
Herpetic stromal keratitis, T cells in, 484
HIV infection (*See* Human immunodeficiency virus infection)
HLAs (*See* Human leukocyte antigens)
Human granulocytic ehrlichiosis
pathogenesis, mouse model, 737
transmission, tick attachment duration for, mouse model, 1422
Human herpesvirus 8
antibodies to, in relatives of Kaposi's sarcoma patients, 1715
in lymphoma, 520
in nasal secretions and saliva, 213
transmission to relatives, 1715
variants, Brazil, 1136
Human herpesvirus 6, in nasal secretions and saliva, 213
Human immunodeficiency virus (type 1)
in blood, vs. semen, 320
in breast milk, 34, 1770
cross-clade inhibition, CD4 monoclonal antibodies in, 1727
DNA, in female genital tract, 1214
in female genital tract, 1100, 1214
gp41 envelope protein
as *Candida albicans* virulence factor, 1057
cytokine production and, 905
gp120 envelope protein, fungal immunity and, 347
gp160 envelope protein, as *Candida albicans* virulence factor, 1057
phenotypes
as prognostic indicator, 625
in zalcitabine treatment, 565
replication
in long-term survivors, 600
in *Mycobacterium avium* complex bacteremia, 595
*Plasmodium falciparum* effects on, 437
reverse transcriptase and, 1221
in tuberculosis, cytokines in, 1332
resistance in, 1506
didanosine, 1207, 1506, 1730
dual, 1521
multiple, 1207
saquinavir, 477
zidovudine, 557, 1207, 1506, 1730
RNA
in anorectal canal, of homosexual men, 571
in cerebrospinal fluid, in lymphocytic meningitis, 473
in female genital tract, 1100, 1214
in genital ulcer disease, 224
in lymphoid tissue
with nondetectable plasma viral RNA levels, 235
in saquinavir resistance, 477
in *Mycobacterium avium* complex bacteremia, 1746
in nucleoside treatment, 625
prognostic value, 617, 1541
in semen and blood
compartmentalization between, 320
in Sub-Saharan Africa, 1742
as surrogate end point, in clinical trials, 761
syncytium-inducing phenotype, 1549
Human immunodeficiency virus infection (type 1)
bacteremia in
*Campylobacter*, quinolone-resistant, 951
*Mycobacterium avium* complex, 1746
treatment, 914
viral replication in, 595
*Campylobacter fetus* bacteremia in, quinolone-resistant, 951
CD8 cell activity in, in pediatric patients, 470
chemokines production in, progression, 331
cytokine expression in, macaque model (simian immunodeficiency virus), 26
cytomegalovirus infections in
prophylaxis with valaciclovir, 48
retinitis, remission, 1080, 1182
viral DNA measurement in, 355
*Encephalitozoon intestinalis* infections in, treatment, 1373
Epstein-Barr virus infections in, in pediatric patients, 1087
vs. Epstein-Barr virus infections, CD8 subsets in, 1083
first-year prognostic indicators, 1541
fungal infections in, envelope protein gp120 and, 347
genital ulcer disease in, viral RNA in, 224
*Helicobacter pylori* infections in, mouse model, 72
hepatitis C in
perinatal transmission, 1480
protease inhibitor effects on, 783
hepatitis G (GB virus C) in, 1723
herpes simplex virus type 2 seropositivity in, epidemiology, Zimbabwe, 481
human herpesvirus 8 infections in, 213

human papillomavirus infections in, epidemiology, in homosexual men, 361
intravaginal microbicidal agents for, normal flora alterations from, 1386
JC virus infections in, 1502
leishmaniasis in, monitoring, 1339
long-term survivors of, replication kinetics in, 600
meningitis in, lymphocytic, 473
microsporidiosis in, 1373
treatment with TNP-470, mouse model, 515
mycobacterial infections in (*See also subheading*: tuberculosis in)
cytokine responses in, 1554
*Mycobacterium avium* complex infections in
bacteremia, 914, 1746
cytokine responses in, 1554
interleukin-10 production in, 586
neurosyphilis in, epidemiology, San Francisco, 931
nonprogressive, replication kinetics in, 600
parvovirus B19 infections in, anemia in, 1773
in pediatric patients (*See under* Pediatric patients)
in pregnancy (*See* Human immunodeficiency virus infection, transmission, vertical)
prognosis, measures for, 617, 625
progression
CD4 T cell receptor repertoire and, 579
chemokines and, 331
Epstein-Barr virus effects on, 1087
vs. virus load, 1541
progressive multifocal leukoencephalopathy in, 1502
RANTES production in, 1091
retinitis in, cytomegalovirus, remission, 1080, 1182
surrogate end points for, in clinical trials, 761
syphilis in, 931, 941
T lymphocytes in, *Pneumocystis carinii* glycoprotein response, 238
transmission
in breast milk, 34, 1770
cat model (feline immunodeficiency virus), 18
endocervical CD4 lymphocytes and, 167
female genital tract viral RNA and, 1100
genital epithelium, 1214
rhesus macaque model, 1247
subtypes B and C in, 227
in syphilis, 941
vertical
human leukocyte antigen concordance and, 551
maternal anti-gp160 antibody titer and, 1737
vs. maternal viral burden, 1097
subtypes B and C in, 227
zidovudine failure in, 557
treatment (*See also* Didanosine; Lamivudine; Zalcitabine; Zidovudine)
in advanced disease, 1514
assessment with viral RNA levels, 40
clinical trials, 761
combination therapy
mouse model, 337
after treatment failure, 1514
cytomegalovirus retinitis remission in, 1080, 1182
granulocyte colony-stimulating factor, 1733
hepatitis C viremia impact in, 783
highly active retroviral therapy (HAART), 1182
indinavir, 1091, 1514
lymphoid tissue virus burden in, 235, 1497
nelfinavir mesylate, 1533
nevirapine, 40, 1514
after nucleoside treatment failure, 1514
nucleosides, 625
ranitidine, 231
RANTES levels in, 1091
ritonavir, 337, 898
ritonavir-saquinavir, 898
saquinavir, 40, 477, 898
SC-49483, 40
vitamin A, 611
tuberculosis in
cytokine responses in, 1554
interleukin-8 receptor expression in, 921
meningitis in, 473
viral replication in, cytokines in, 1332
vaccination, 301
canarypox vector in, 1230
cross-clade inhibition and, 1727
cytokine expression in, macaque model (simian immunodeficiency virus), 26
efficacy, 310
mouse model, 889
rhesus macaque model, 1247
virus load in
in female genital tract, 1214
vs. human papillomavirus infections, 571
in long-term survivors, 600
in lymphoid tissue, 1497
measurement, 1221
prognostic value, 1541
in Sub-Saharan Africa, 1742
vaccination and, 310
vs. vertical transmission risk, 1097
vitamin A supplementation and, 611
Human immunodeficiency virus infection (type 2), Nef protein truncation in, 65
Human leukocyte antigens
in cytotoxic T cell response to measles virus antigens, 1282
human immunodeficiency virus vertical transmission and, 551
rubella vaccine-induced arthropathy associations, 5
in schistosomiasis, hepatic fibrosis prognosis and, 1682
Human papillomaviruses
antibodies to, stability over time, 1710
infections
epidemiology, in homosexual men, 361
vs. HIV virus load, in anorectal canal, homosexual men, 571
Human T lymphotropic virus type 1, infections, interleukin-10 down-regulation in, 1489
Humoral immune response (*See also* Antibody[ies])
in *Chlamydia trachomatis* pelvic inflammatory disease, 714
to human immunodeficiency virus, transmission enhancement and, 1737
in human T lymphotropic virus type 1 infections, 1489
in malaria, 1132
to *Plasmodium falciparum*, 1358
in schistosomiasis, 1364
in simian immunodeficiency virus infection, 1771
to tetanus-diphtheria vaccine, during malaria prophylaxis, 1762
to varicella vaccine, 1701
Hydroxyurea, for latent Epstein-Barr virus infections, in vitro studies, 1194

Imipenem, in *Escherichia coli* culture, endotoxin and cytokine levels and, 1302
Immune response (*See also* Cellular immune response; Humoral immune response)

to *Borrelia burgdorferi*, tickborne vs. host-adapted, mouse model, 395
in *Chlamydia trachomatis* pelvic inflammatory disease, 714
to *Cryptococcus neoformans* polysaccharide, mouse model, 1647
in feline immunodeficiency virus inoculation, 18
to *Leishmania*, 1345
to *Plasmodium falciparum*, in infants, 819
to *Pneumocystis carinii* glycoprotein, in HIV infection, 238
in schistosomiasis, variation in, 1364
to *Staphylococcus aureus* enterotoxin B mutation, 1013
to *Trypanosoma cruzi trans*-sialidase, mouse model, 431
Immunization (*See* Vaccination)
Immunoassays, dot blot, for *Orientia tsutsugamushi*, 800
Immunoblot test, in *Chlamydia pneumoniae* infections, 720
Immunodeficiency (*See also* Human immunodeficiency virus infection; Transplantation)
common variable, GB virus C infection in, 1719
Immunoglobulin(s)
in enterotoxigenic *Escherichia coli* diarrhea prophylaxis, 662
in passive immunization, for simian immunodeficiency virus, 1247
Immunoglobulin A, in simian immunodeficiency virus immunization, 26
Immunoglobulin G
avidity for *Streptococcus pneumoniae*, after vaccination, 1614
degradation, *Entamoeba histolytica* neutral cysteine proteinase in, 508
Immunostimulating complexes, in influenza prophylaxis, 1266
Indinavir, for HIV infection
advanced, 1514
RANTES levels in, 1091
Inflammation, interleukin-1 receptors in, mouse model, 1398
Influenza
pig model, 1076
prophylaxis, immunostimulating complexes in, 1266
resistance in, 863
treatment, 1260
vaccination
vs. immunostimulating complexes, 1266
trivalent live cold-adapted, 1394
Integrins
in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 107
in *Streptococcus pneumoniae* adhesion to neutrophils, 977
Intercellular adhesion molecules
in dengue hemorrhagic fever, 778
in *Streptococcus pneumoniae* adhesion to neutrophils, 977
Interferon(s), for hepatitis C, nonstructural 5A gene interferon sensitivity determining region and, 839
Interferon-$\alpha$
in bronchoalveolar lavage fluid, in influenza, pig model, 1076
in hepatitis C viremia, viral dynamics and, 1475
Interferon-$\alpha$-2a, for HIV infection, assessment with viral RNA levels, 40
Interferon-$\gamma$
production
in *Chlamydia pneumoniae* replication inhibition, 1326
in chronic fatigue syndrome, 451
down-regulation, in schistosomiasis, 1433
in HIV infection, 905
in mycobacterial infections, 1554
in *Pneumocystis carinii* infections, 238
in tuberculosis, 1332
in human T lymphotropic virus type 1 infections, 1489
in leishmaniasis, 1345, 1687
in malaria resistance, mouse model, 1674
in simian immunodeficiency virus infection, 26
therapeutic, for visceral leishmaniasis, 815
Interleukin(s)
in herpes simplex virus infections, recurrent, 827
in HIV infection, 905
in tuberculosis, 1332
in human T lymphotropic virus type 1 infections, 1489
in leishmaniasis, 1345
cutaneous, 1687
visceral, 815
in malaria resistance, mouse model, 1674
in simian immunodeficiency virus infection, 26
Interleukin-1
in bronchoalveolar lavage fluid, in influenza, pig model, 1076
peptidoglycan activation, 1629
Interleukin-1 receptors
antagonist to, in yellow fever vaccination, 774
in inflammation, mouse model, 1398
Interleukin-1$\beta$
down-regulation, in meningococcal infections, 1401
in streptococcal group B infections, lactic acid effects on, 1418
Interleukin-4
in mycobacterial infections, HIV infection effects on, 1554
in *Pneumocystis carinii* infections, in HIV infection, 238
Interleukin-5, down-regulation, in schistosomiasis, 1433
Interleukin-6
in bacteremia, *Mycobacterium avium* complex, in HIV infection, 1746
in dengue hemorrhagic fever, 778
in *Escherichia coli* culture, vs. endotoxin release, 1302
in interleukin-8 production, in respiratory syncytial virus infections, 1275
in osteomyelitis, 1582
*Plasmodium falciparum* induction, human immunodeficiency virus replication and, 437
synthesis, complement regulation, 1622
Interleukin-8
in bronchial secretions, in cystic fibrosis, 1413
cryptococcal glucuronoxylomannan effects on, 260
in cytomegalovirus dissemination, 1465
in enteroaggregative *Escherichia coli* diarrhea, 88
in neutrophils, nitric oxide effects on, 116
in osteomyelitis, 1582
receptors for, in HIV infection with tuberculosis, 921
in respiratory syncytial virus infections, 1275
Interleukin-10
down-regulation, in human T lymphotropic virus type 1 infections, 1489
in *Mycobacterium avium* complex infections, in HIV infection, 586
IS1548 insertion element, in group B streptococcal endocarditis, 967
Isoniazid, for *Mycobacterium bovis* meningitis, rabbit model, 1563
Itraconazole, for *Candida albicans* infections, amphotericin B interactions with, mouse model, 1660

Japanese encephalitis virus, vaccination, 221
JC virus, infections, in HIV infection, 1502
Joint disorders, in rubella vaccination, human leukocyte antigen associations with, 5
Junin virus, vaccination, 277

Kala-azar (visceral leishmaniasis)
in HIV infection, monitoring, 1339
treatment, cytokine responses in, 815
Kanamycin, resistance to, mycobacteria, 1573
Kaposi's sarcoma
human herpesvirus 8 detection in, 213

transmission, to relatives, 1715
*katG* gene, in tuberculosis pathogenesis, mouse and guinea pig models, 1030
Keratinocytes, herpes simplex virus in, recurrence and, 827
Keratitis, herpes simplex virus, corneal T cells in, 484
Killer toxin-like antibodies, mycobactericidal activity, 807
Kirby, William M. M., tribute to, 1

β-Lactamase, *Staphylococcus aureus*, in wound infections, guinea pig model, 701
Lactic acid, in streptococcal group B infections, cytokine production and, 1418
Lactobacilli, vaginal, microbicidal agent effects on, 1386
Lactoferrin, in enteroaggregative *Escherichia coli* diarrhea, 88
Lamivudine
for hepatitis B, resistance to, 1382
for HIV infection
advanced, 1514
mouse model, 337
RANTES levels in, 1091
resistance to, 1521
Langerhans' cells, endocervical, in sexually transmitted diseases, 167
*Leishmania*, immune response to, 1345
*Leishmania major*, infections
progression, immunologic determinants, 1687
treatment with ganciclovir, mouse model, 188
Leishmaniasis
cutaneous
progression, immunologic determinants, 1687
vaccination, 1352
vaccination, mouse model, 188
visceral
in HIV infection, monitoring, 1339
treatment, cytokine responses in, 815
Leprosy, susceptibility to, *NRAMP1* gene in, 133
*Leptospira*, uveitis, polymerase chain reaction in, 1314
Lettuce, *Escherichia coli* O157:H7 infections from, 1588
Leukopenia, in ehrlichiosis, mouse model, 737
Leukotriene(s), in *Toxoplasma gondii* infections, mast cell–mediated, 1437
Leukotriene $B_4$, in neutrophil stimulation, cyclic guanosine monophosphate response to, 116
Lewis antigens, urinary tract infections and, 1296
Ligase chain reaction, for *Chlamydia trachomatis*, in urine, 417
*Limulus* antilipopolysaccharide factor, for endotoxemia, mouse model, 388
Lipopeptides, treponemal, in HIV gene expression, 941
Lipopolysaccharide (*See also* Endotoxemia)
vs. cytokine production, 1302
in nitric oxide synthase inhibition, mouse model, 127
Lipoproteins
low-density, in foam cell formation, *Chlamydia pneumoniae* and, 725
treponemal
in HIV gene expression, 941
in species differentiation, 1036
Listeriosis, epidemiology, France, 155
Liver
fibrosis, in schistosomiasis, human leukocyte antigens and, 1682
transplantation, adenovirus infections in, 459
L-NAME ($N^G$-γ-L-arginine methyl ester), in nitric oxide synthase inhibition, mouse model, 127
L-selectin, in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 107
Lung function, respiratory syncytial virus effects on, mouse model, 269
Lyme disease (*See also Borrelia burgdorferi*)
carditis, mouse model, 242
cerebrospinal fluid analysis in, matrix metalloproteinases in, 401
Lymphocytes (*See* B cells; T cells)
Lymphocytic meningitis, in HIV infection, 473
Lymphoid tissues, HIV RNA in
in bitherapy, 1497
multidrug therapy effects on, mouse model, 337
with nondetectable plasma viral RNA levels, 235
saquinavir resistance mutations in, 477
Lymphoma
Burkitt's, cell line, Epstein-Barr virus reactivation in, viral episome loss in, 1705
human herpesvirus 8 in, 520
Lymphoproliferative diseases, prevention, latent Epstein-Barr virus eradication in, 1194
Lysozyme, in body fluids, in bacterial meningitis, 102

Macrophage inflammatory proteins
in herpes simplex virus infections, recurrent, 827
HIV progression and, 331
Macrophages
in *Chlamydia pneumoniae* dissemination, mouse model, 1322
foam cell formation from, *Chlamydia pneumoniae* and, 725
in Lyme carditis, mouse model, 242
Major histocompatibility complex (*See also* Human leukocyte antigens)
down-regulation, varicella-zoster virus in, 1390
*Staphylococcus aureus* enterotoxin B binding to, 1013
Malaria
antigens, human immunodeficiency virus replication and, 437
cerebral, cerebrospinal fluid analysis in, 1064
clinical features, 1776
clinical protection from, in infants, 819
humoral immune response in, 1132
prophylaxis, tetanus-diphtheria vaccination during, 1762
resistance in, 1429
mouse model, 1674
risks of, in pediatric patients, 819
transmission, reduction, 1358
vaccination, 1664
Malnutrition, in enteroaggregative *Escherichia coli* diarrhea, 88
Mast cells, in *Toxoplasma gondii* infections, leukotrienes in, 1437
Mathematical models, influenza drug resistance, 863
Matrix metalloproteinases, in cerebrospinal fluid, in Lyme disease, 401
Measles virus
antigens, cytotoxic T cell response to, human leukocyte antigens and, 1282
epidemiology, genetic analysis (1995–1996), 204
Meningitis
bacterial, peptidoglycan-degrading enzymes in, 102
cryptococcal, glucuronoxylomannan actions in, 260
*Escherichia coli*, phylogenetic analysis, in neonates, 642
lymphocytic, in HIV infection, 473
*Mycobacterium bovis*, treatment, rabbit model, 1563
neonatal, aminoguanidine effects on, rat model, 692
streptococci group B
cytokine production in, lactic acid effects on, 1418
epidemiology, Canada, 1754
*Streptococcus pneumoniae*, rat model, 986
syphilitic, in HIV infection, epidemiology, San Francisco, 931
treatment, nitric oxide, 766
tuberculous, rabbit model, 1563
Meningococci
group B
invasive, epidemiology, Canada, 1754
meningitis, rat model, 692

vaccination, 683
infections
B:4:P1.4 strain, epidemiology, New Zealand, 497
cytokine down-regulation in, 1401
meningitis, in HIV infection, 473
Meropenem, in *Escherichia coli* culture, endotoxin and cytokine levels and, 1302
Merozoite surface protein 1, in *Plasmodium vivax* infection relapses, 511
Metalloproteinases, in cerebrospinal fluid, in Lyme disease, 401
Methacholine, for respiratory syncytial virus infection, mouse model, 269
Methicillin, resistance to, *Staphylococcus aureus*, rat model, 146
Microsporidiosis, treatment
in HIV infection, 1373
TNP-470, mouse model, 515
Milk immunoglobulin, in enterotoxigenic *Escherichia coli* diarrhea prophylaxis, 662
Molecular amplification assays, for *Chlamydia trachomatis* in urine, 417
Molluscum contagiosum virus, antigenic polypeptides, 284
Monoclonal antibody(ies)
CD4, in HIV inhibition, 1727
in cryptococcosis
mouse model, 1639
polysaccharide clearance and, mouse model, 1647
in human immunodeficiency virus vaccination, mouse model, 889
mycobactericidal activity, 807
to respiratory syncytial virus, in passive immunization, 874
for respiratory syncytial virus infections, 1073
Monocytes
activation of, in sepsis, granulocyte-macrophage colony-stimulating factor in, 107
antifungal activity, HIV envelope protein gp120 effects on, 347
cytokine production in, in HIV infection, 905
endocervical, in sexually transmitted diseases, 167
HIV gene expression in, *Treponema pallidum* effects on, 941
interleukin-10 production in, in *Mycobacterium avium* complex infections, in HIV infection, 586
interleukin-6 synthesis in, complement regulation, 1622
peptidoglycan from, in cytokine release, 1629
*mrp* gene, streptococci group A, virulence and, mouse model, 991
Mucosal immune response
in cholera, in endemic region, 1594
to feline immunodeficiency virus, 18
to herpes simplex virus type 1, mouse model, 1451
to herpes simplex virus type 2, mouse model, 1155
Multiple drug resistance (*See under* Drug resistance)
Mumps, vaccination, hemagglutinin-neuraminidase gene nucleotide sequence, 265
Mutations
cytomegalovirus, 1176
hepatitis B virus, in lamivudine therapy, 1382
hepatitis B virus core antigen, 264
human immunodeficiency virus, 1730
multiple resistance in, 1207
for saquinavir resistance, 477
mycobacteria, aminoglycoside resistance in, 1573
*Mycobacterium tuberculosis*, 1107
mouse and guinea pig models, 1030
reverse transcriptase, HIV resistance in, 1506
*Staphylococcus aureus* enterotoxin B, immune response to, 1013
*Toxoplasma gondii*, 1128
*Mycobacterium abscessus*, resistance in, 1573
*Mycobacterium avium* complex
bacteremia
in HIV infection, 1746
treatment, 914
viral replication in, 595
treatment with rifabutin, uveitis in, 252
infections, in HIV infection
cytokine responses in, 1554
interleukin-10 production in, 586
skin tests for, vs. tuberculosis, 730
*Mycobacterium bovis*, meningitis, treatment, rabbit model, 1563
*Mycobacterium chelonae*, resistance in, 1573
*Mycobacterium leprae*, susceptibility to, *NRAMP1* gene and, 133
*Mycobacterium tuberculosis* (*See also* Tuberculosis)
antigens, in HIV replication, 1332
epidemiology, San Francisco, 1104
genotypes, stability, 1107
treatment, toxin-like antibodies in, 807
virulence factors, mouse and guinea pig models, 1030
*Mycoplasma pneumoniae*, pneumonia, prophylaxis with azithromycin, 161

Natural killer cells, cytokine production in, in HIV infection, 905
Nef protein truncation, in HIV type 2, 65
*Neisseria gonorrhoeae*
infections, cytomegalovirus seroconversion and, 1188
resistance in, fluoroquinolones, 677
*Neisseria meningitidis*
epidemiology, serogroup B, electrophoretic type 15, Canada, 1754
vaccination, 683
Nelfinavir mesylate, for HIV infection, 1533
Neomycin, resistance to, mycobacteria, 1573
Neonatal infections (*See also* Human immunodeficiency virus infection, transmission, vertical)
hepatitis B virus, 1378
meningitis
*Escherichia coli*, phylogenetic analysis, 642
rat model, 692
simian immunodeficiency virus vaccination, rhesus macaque model, 1247
streptococci group B, capsular polysaccharide types, 790
Neopterin, in cerebrospinal fluid, in cerebral malaria, 1064
Neu, Harold Conrad, tribute to, 1449
Neuroborreliosis, cerebrospinal fluid analysis in, matrix metalloproteinases in, 401
Neurologic disorders, cytomegalovirus, rhesus monkey model, 446
Neurosyphilis, epidemiology, in HIV infection, San Francisco, 931
Neurotoxin, eosinophil-derived, for respiratory syncytial virus infections, 1458
Neutral cysteine proteinase, *Entamoeba histolytica*, in immunoglobulin G degradation, 508
Neutralizing antibodies
in HIV vaccination, 301, 889
for respiratory syncytial virus infections, 1073
Neutrophils
chemotaxis, nitric oxide effects on, 116
endothelial cell interactions with, in cytomegalovirus dissemination, 1465
interleukin-8 receptor expression on, in HIV infection with tuberculosis, 921
migration, cryptococcal glucuronoxylomannan effects on, 260
*Streptococcus pneumoniae* adhesion to, 977
Nevirapine, for HIV infection
advanced, 1514
assessment with viral RNA levels, 40
Nitrate, reduction, in endotoxemia, doxycycline in, mouse model, 489

Nitric oxide
inhibition, doxycycline in, mouse model, 489
for meningitis, 766
rat model, 692
metabolites of, in cerebrospinal fluid, in cerebral malaria, 1064
in neutrophil chemotaxis, 116
for sepsis, 766
Nitric oxide synthase
inhibition, in endotoxic shock, mouse model, 127
in malaria resistance, mouse model, 1674
for meningitis, 766
rat model, 692
for sepsis, 766
Nonoxynol-9, vaginal flora alterations from, 1386
Nose, secretions from, human herpesvirus 8 in, 213
Nosocomial infections, enterococci, vancomycin-resistant, genotyping, 368
*NRAMP1* gene, leprosy susceptibility and, 133
NSP4 protein, in rotavirus diarrhea pathogenesis, mouse model, 455
Nuclear factor-κB
in HIV gene expression, 941
in interleukin-8 production, in respiratory syncytial virus infections, 1275
Nutrition, parenteral, in endotoxemia, coagulation in, 793
NYVAC-Pf7 vaccine, for malaria, 1664

O antigen, *Escherichia coli*, 1774
Ocular infections (*See* Eye infections)
Oligonucleotide-primed amplification assay, for *Streptococcus agalactiae* genomic diversity, 1308
*Orientia tsutsugamushi*, antibodies to, dot blot immunoassay for, 800
Oropharyngeal carriage, *Haemophilus influenzae*, after vaccination, 1758
Osteomyelitis, acute-phase response in, 1582
Otitis media, in influenza, prophylaxis, 1260
Outbreaks
*Escherichia coli* O157:H7 infections, foodborne, 1588
*Mycoplasma pneumoniae* pneumonia, azithromycin prophylaxis in, 161
*Shigella sonnei* infections, in traditionally observant Jewish communities, 1405
Outer membrane proteins, in meningococci group B vaccine, immunogenicity, 683
Oxidative burst activity (*See* Respiratory burst activity)

P adhesin, *Escherichia coli*, *papG* gene alleles, in cystitis, 97
p24 antigen, measurement, as HIV infection prognostic indicator, 617, 625
*papG* gene alleles, *Escherichia coli*
bacteremia, 651
cystitis, 97
uropathogenic, 1120
Parenteral nutrition, in endotoxemia, coagulation in, 793
Parvovirus B19, infections, in HIV infection, anemia in, 1773
Pediatric patients (*See also* Neonatal infections)
bone marrow transplantation in, cytomegalovirus monitoring in, 519
bronchiolitis in, Simkania Z, 1425
bronchopulmonary dysplasia in, respiratory syncytial virus vaccination in, 467
dengue hemorrhagic fever in, pathophysiology, 778
diarrhea in
*Cryptosporidium*, epidemiology, Brazil, 754
*Escherichia coli*, intestinal inflammation in, 88
rotavirus, epidemiology (1993–1995), 13
*Helicobacter pylori* infections in, virulence factors, 247
hepatitis C in, perinatal transmission, 1480
human immunodeficiency virus infection in
CD8 cell activity in, 470
Epstein-Barr virus infection with, 1087
rhesus macaque model, 1247
risk, vs. maternal virus load, 1097
transmission, 227
in breast milk, 34, 1770
human leukocyte antigen concordance and, 551
maternal anti-gp160 antibody titer and, 1737
vs. maternal viral burden, 1097
subtypes B and C in, 227
in zidovudine failure, 557
viral phenotypes in, 565
influenza vaccination in, 1394
leishmaniasis vaccination in, 1352
malaria risks in, 819
pathogen transmission among, surrogate markers for, 881
respiratory infections in, *Chlamydia pneumoniae*, antibody response in, 720
*Streptococcus pneumoniae* resistance in, 1003
Pelvic inflammatory disease, *Chlamydia trachomatis*, immune response in, 714
Penicillinase, in methicillin-resistant *Staphylococcus aureus*, cefamandole interaction with, rat model, 146
Peptic ulcer disease, risk factors for, 1124
Peptidoglycans
in cytokine release, 1629
enzymes degrading, in body fluids, in bacterial meningitis, 102
Peritonitis, gram-negative, rabbit model, 668
Phagocytosis, *Helicobacter pylori* urease in, 803
Phosphatidylethanolamine, *Helicobacter* binding to, bovine colostrum effects on, 955
Phospholipids, alveolar type II cells, *Pneumocystis carinii* glycoprotein A inhibition, 182
Plaque reduction assay, modified, in herpes simplex virus resistance screening, 217
*Plasmodium berghei* XAT, resistance to, mouse model, 1674
*Plasmodium falciparum*
human immunodeficiency virus replication and, 437
infections
cerebral, cerebrospinal fluid analysis in, 1064
clinical features, 1776
risks of, in pediatric patients, 819
resistance in, 1429
transmission, reduction, 1358
vaccination, 1664
*Plasmodium vivax*
infections, relapses in, molecular analysis in, 511
persistent humoral immune response to, 1132
Pneumococci (*See Streptococcus pneumoniae*)
*Pneumocystis carinii*
major surface glycoprotein, T lymphocyte response, in HIV infection, 238
pneumonia
pathogenesis, 182
treatment, rat model, 1046
Pneumocytes, *Streptococcus pneumoniae* adhesion to, 977
Pneumonia
adenovirus, in liver transplantation, 459
eosinophilic, in cryptococcosis, mouse model, 1639
influenza virus, pig model, 1076
*Mycoplasma pneumoniae*, prophylaxis with azithromycin, 161
*Pneumocystis carinii*
pathogenesis, 182

treatment, rat model, 1046
*Streptococcus pneumoniae*
pathogenesis, 977
rat model, 986
*pol* gene, HIV, mutations, drug resistance in, 1207
Polymerase chain reaction
for *Chlamydia pneumoniae*, mouse model, 1322
for *Chlamydia trachomatis*, in urine, 417
for *Cryptosporidium parvum*, 1443
for cytomegalovirus, in HIV infection, 57
for ehrlichiosis, mouse model, 737
for *Escherichia coli*, 642
*papG* gene, 651
uropathogenic, 1120
for human herpesvirus 8
in central nervous system lymphoma, 520
in nasal secretions and saliva, 213
for human immunodeficiency virus, in breast milk, 34, 1770
for *Leptospira* uveitis, 1314
for Lyme carditis, mouse model, 242
for *Plasmodium falciparum* enzyme genotypes, 1429
for *Plasmodium vivax* infection relapses, 511
reverse transcription
for *Leishmania major*, 1687
for measles virus, 204
for respiratory syncytial virus, 1458
in treponemal differentiation, 1036
Polymorphonuclear leukocytes
cryptococcal glucuronoxylomannan effects on, 260
cytomegalovirus DNA in, in HIV infection, 355
interleukin-8 receptor expression on, in HIV infection with tuberculosis, 921
Polypeptides, molluscum contagiosum virus, 284
Postpartum vaccination, rubella, arthropathy in, human leukocyte antigen associations with, 5
Pregnancy
cytomegalovirus in, 1170
GB virus C transmission in, 1202
hepatitis B virus infection in, vertical transmission, 1378
HIV infection (*See also* Human immunodeficiency virus infection, transmission, vertical)
human papillomavirus antibodies in, 1710
Primaquine, in malaria prophylaxis, tetanus-diphtheria vaccination during, 1762
Progressive multifocal leukoencephalopathy, in HIV infection, 1502
Prophylaxis (*See also* Vaccination)
aspergillosis, in bone marrow transplantation, 1775
cytomegalovirus infections, in HIV infection, 48, 57
*Escherichia coli* travelers' diarrhea, 662
*Haemophilus ducreyi* infections, 1608
human immunodeficiency virus infection, zidovudine in, 557
influenza, 1260
leishmaniasis, mouse model, 188
malaria
antibody detection in, 1132
tetanus-diphtheria vaccination during, 1762
*Mycoplasma pneumoniae* pneumonia, 161
*Pneumocystis carinii* pneumonia, rat model, 1046
*Staphylococcus aureus* endocarditis, methicillin-resistant, rat model, 146
*Staphylococcus aureus* wound infections, guinea pig model, 701
Protease inhibitors, for HIV infection
hepatitis C viremia and, 783
nelfinavir mesylate, 1533
residual viral DNA in lymphoid tissue, 235
*Pseudomonas aeruginosa*, recombinant exoprotein A, in *Escherichia coli* O157 vaccine, 383
Pulmonary surfactant
abnormalities, in *Pneumocystis carinii* pneumonia, 182
for *Pneumocystis carinii* pneumonia, rat model, 1046
Pulsed-field gel electrophoresis, for *Shigella sonnei* identification, 1405
Purified protein derivative
in HIV replication, 1332
in skin testing, for mycobacterial infections, 730
Pyrimethamine, resistance to, *Plasmodium falciparum*, 1429

Quinolones, resistance to, *Campylobacter fetus*, 951

Rabies, vaccination, persistence, 1290
Ranitidine, for HIV infection, 231
RANTES
in herpes simplex virus infections, recurrent, 827
in HIV infection, 1091
progression and, 331
RAV 9395 recombinant virus, in herpes simplex virus type 2 vaccination, guinea pig model, 1143
Recall antigen response, in HIV replication, 1332
Rectum
cancer, in human papillomavirus infections, in homosexual men, 361
HIV in, in homosexual men, 571
Red blood cells (*See* Erythrocytes)
Resistance
to drugs (*See* Drug resistance)
to hepatic fibrosis, in schistosomiasis, 1682
to malaria, mouse model, 1674
to schistosomiasis, 1364
Respiratory burst activity
*Helicobacter pylori* urease in, 803
restoration, in sepsis, granulocyte-macrophage colony-stimulating factor in, 107
Respiratory infections (*See also* Pneumonia; Respiratory syncytial virus, infections; Tuberculosis)
antibiotics for, France, 492
*Chlamydia pneumoniae*, antibody response in, 720
*Mycobacterium avium* complex, skin tests for, 730
Respiratory syncytial virus
infections
antibody measurement in, in elderly persons, 463
interleukin-8 expression in, 1275
mouse model, 269
treatment, 1073, 1458
vaccination
bovine model, 874
in bronchopulmonary dysplasia, 467
Restriction fragment length polymorphism, in treponemal differentiation, 1036
Retinitis, cytomegalovirus
ganciclovir-resistant, 770, 1176
in HIV infection, remission, 1080, 1182
Retinoic acid receptor elements, in HIV, 611
Reverse transcriptase
assays for, in HIV virus load measurement, 1221
inhibitors, for HIV infection, residual viral DNA in lymphoid tissue, 235
mutations, HIV resistance in, 1506
Rifabutin, for *Mycobacterium avium* complex bacteremia, uveitis from, 252
Rifampicin, for *Mycobacterium bovis* meningitis, rabbit model, 1563
Rillettes, listeriosis from, in France, 155

Rimantadine, for influenza, 1260
Ritonavir, for HIV infection
  mouse model, 337
  with saquinavir, 898
RNA, human immunodeficiency virus (*See* Human immunodeficiency virus, RNA)
RNase 2, for respiratory syncytial virus infections, 1458
Rotavirus, diarrhea
  epidemiology (1993–1995), 13
  pathogenesis, mouse model, 455
Rubella, vaccine for, arthropathy in, human leukocyte antigen associations with, 5

Salicylic acid, in *Staphylococcus epidermidis* biofilm inhibition, 501
Saliva, human herpesvirus 8 in, 213
Saquinavir, for HIV infection
  assessment with viral RNA levels, 40
  resistance, 477
  with ritonavir, 898
SC-49483, for HIV infection, assessment with viral RNA levels, 40
Scarring trachoma, chlamydial heat-shock proteins in, 256
Schistosomiasis
  cytokine down-regulation in, 1433
  hepatic fibrosis in, human leukocyte antigens and, 1682
  resistance to, lymphocyte response in, 1364
Scrub typhus, dot blot immunoassay for, 800
Selectins, in sepsis, granulocyte-macrophage colony-stimulating factor effects on, 107
Semen
  hepatitis C virus absence in, 848
  human immunodeficiency virus in
    vs. blood, 320
    in genital ulcer disease, 224
    in Sub-Saharan Africa, 1742
Sensitin, *Mycobacterium avium*, in skin testing, 730
Sepsis
  complement activation in, C-reactive protein in, 81
  gram-negative, tissue factor pathway inhibitor for, rabbit model, 668
  streptococci group B
    capsular polysaccharides, in neonates, 790
    cytokine production in, lactic acid effects on, 1418
  treatment
    doxycycline, mouse model, 489
    granulocyte-macrophage colony-stimulating factor for, 107
    nitric oxide, 766
Sexually transmitted diseases (*See also specific disease*)
  cytomegalovirus seroconversion and, 1188
*Shigella sonnei*, infections, outbreaks, in traditionally observant Jewish communities, 1405
Shock
  in dengue hemorrhagic fever, pathophysiology, cytokines in, 778
  endotoxic
    *Limulus* antilipopolysaccharide factor in, mouse model, 388
    nitric oxide synthase inhibition in, mouse model, 127
  septic (*See* Sepsis)
*trans*-Sialidase, *Trypanosoma cruzi*, in immune response enhancement, mouse model, 431
Simian immunodeficiency virus infection
  CD4 cell response in, 1771
  cytokine expression in, macaque model, 26
  vaccination, 1247
Simkania Z bronchiolitis, in pediatric patients, 1425
Sin Nombre virus, antigens, tissue distribution, 1696
Skin lesions
  herpes simplex virus type 2, acyclovir-resistant, 543
  *Leishmania*
    progression, immunologic determinants, 1687
    vaccination, 1352
  molluscum contagiosum virus, antigens, 284
  streptococci group A, virulence factors, mouse model, 991
Skin tests, for mycobacterial infections, 730
Slime-associated proteins, *Staphylococcus epidermidis*, salicylic acid–mediated inhibition, 501
Sodium antimony gluconate, for visceral leishmaniasis, 815
Spleen, cytokines in, in visceral leishmaniasis, 815
*Staphylococcus aureus*
  infections, in cystic fibrosis, 1023
  inflammation from, interleukin-1 receptors in, mouse model, 1398
  methicillin-resistant, endocarditis, prophylaxis, rat model, 146
  small colony variant strains, in cystic fibrosis, 1023
  vaccination, mouse model, 1013
  wound infections, guinea pig model, 701
*Staphylococcus epidermidis*, biofilm, salicylic acid–mediated inhibition, 501
Streptococci
  group A
    invasive
      epidemiology, 1773
      isolate location and, 1600
    resistance in, erythromycin, 786
    typing, field inversion gel electrophoresis in, 504
    virulence factors, 1600
      in skin infections, mouse model, 991
  group B
    endocarditis, IS1548 insertion element in, 967
    infections
      capsular polysaccharide types, in neonates, 790
      cytokines in, lactic acid effects on, 1418
    invasive
      highly encapsulated, 1116
      serotype distribution, 998
    vaccination, serotype distribution, 998
*Streptococcus agalactiae*, genomic diversity, 1308
*Streptococcus pneumoniae*
  anticapsular antibodies, rat model, 986
  colonization, drug-resistant, 1003
  infections, multidrug-resistant, mouse model, 707
  phase variation in, opaque vs. transparent, mouse model, 368
  pneumonia, pathogenesis, 977
  resistance in
    child care facility, 1003
    mouse model, 707
  vaccination, 1614
    rat model, 986
  virulence factors, 977
    mouse model, 368
*Streptococcus pyogenes* (*See* Streptococci, group A)
Strongyloidiasis, immunodiagnosis, 196
Sulfadoxine, resistance to, *Plasmodium falciparum*, 1429
Superantigens
  staphylococcal, modification, in vaccine development, mouse model, 1013
  *Toxoplasma gondii* antigens as, 746
Surfactant, pulmonary
  abnormalities, in *Pneumocystis carinii* pneumonia, 182
  for *Pneumocystis carinii* pneumonia, rat model, 1046
Surgical infections, *Staphylococcus aureus*, guinea pig model, 701
Susceptibility testing

amphotericin B, for *Candida* fungemia, 425
cytomegalovirus, 823
Swimming, *Escherichia coli* O157:H7 infections from, 962
Syncytium-inducing phenotype, HIV, 1549
Syphilis
differentiation from other treponemal diseases, 1036
epidemiology, in HIV infection, San Francisco, 931
in HIV infection, transmission and, 941

T cells
CD4
corneal, in herpetic stromal keratitis, 484
endocervical, in sexually transmitted diseases, 167
in HIV infection
in genital ulcer disease, 224
granulocyte colony-stimulating factor effects on, 1733
interleukin-10 production in, in *Mycobacterium avium* complex infections, 586
measurement, 617, 1541
in nucleoside treatment, 625
as prognostic indicator, 1541
receptor repertoire, 579
vs. semen viral RNA, 320
response
in simian immunodeficiency virus infection, 1771
to *Toxoplasma gondii* antigens, 746
CD8
in Epstein-Barr virus infections, 1083
in HIV infection, 1083
*Helicobacter pylori* effects on, mouse model, 72
interleukin-10 production in, in *Mycobacterium avium* complex infections, 586
noncytotoxic activity, 470
response to feline immunodeficiency virus mucosal inoculation, cat model, 18
CD14, complexed with peptidoglycan, actions on endothelial and epithelial cells, 1629
CD34, in HIV infection, granulocyte colony-stimulating factor effects on, 1733
cytokine production in
in HIV infection, 905
in simian immunodeficiency virus infection, 26
cytotoxic (*See also* T cells, CD8)
in HIV vaccination, 301
induction, by influenza immunostimulating complexes, 1266
response
to *Leishmania*, 1345
to measles virus antigens, human leukocyte antigens and, 1282
interferon-$\gamma$ production by, in chronic fatigue syndrome, 451
in Lyme carditis, mouse model, 242
*Pneumocystis carinii* glycoprotein response, in HIV infection, 238
proliferation, in human T lymphotropic virus type 1 infections, 1489
in schistosomiasis, 1364
Tampons, toxin production in, vs. fiber composition, 824
3tC (*See* Lamivudine)
Teichoic acid
*Staphylococcus epidermidis*, salicylic acid–mediated inhibition, 501
*Streptococcus pneumoniae*, virulence and, mouse model, 368
Tetanus-diphtheria vaccination, during malaria prophylaxis, 1762
Thalidomide, for *Mycobacterium bovis* meningitis, rabbit model, 1563
Thrombosis, in parenteral nutrition, in endotoxemia, 793
Thymidine kinase
deficiency, in herpes simplex virus, 543
with ganciclovir, for leishmaniasis, mouse model, 188
Ticks
attachment duration, for ehrlichiosis transmission, mouse model, 1422
*Borrelia burgdorferi* adaptation in, mouse model, 395
microorganism mixtures in, mouse model, 409
Tissue factor pathway inhibitor, for gram-negative peritonitis, rabbit model, 668
Tobramycin, resistance to, mycobacteria, 1573
Toxic shock
*Limulus* antilipopolysaccharide factor in, mouse model, 388
nitric oxide synthase inhibition in, mouse model, 127
Toxic shock syndrome, tampon composition and, 824
Toxin-like antibodies, mycobactericidal activity, 807
*Toxoplasma gondii*
antigens, as superantigens, 746
host defenses against, 1437
infections, mast cell–mediated, leukotrienes in, 1437
resistance in, artemisinin, 1128
Trachoma, chlamydial heat-shock proteins in, 256
Transcription factors, in interleukin-8 production, in respiratory syncytial virus infections, 1275
Transforming growth factor-$\beta$, in HIV replication, in tuberculosis, 1332
Transplantation
bone marrow
aspergillosis prevention in, 1775
cytomegalovirus monitoring after, 519
liver, adenovirus infections in, 459
Travelers' diarrhea
enteroaggregative *Escherichia coli*, 1409
outbreak, Galapagos Islands, 1041
prophylaxis, *Escherichia coli*, 662
*Treponema*, differentiation, 1036
*Treponema pallidum*, in HIV infection
epidemiology, San Francisco, 931
transmission and, 941
Trichomoniasis, endocervical CD4 lymphocytes in, 167
*Trypanosoma cruzi*, *trans*-sialidase, in immune response enhancement, mouse model, 431
Tryptophan catabolism, in *Chlamydia pneumoniae* replication inhibition, 1326
Tuberculoma, meningitis in, in HIV infection, 473
Tuberculosis (*See also Mycobacterium tuberculosis*)
drug-susceptible, New York City, 1138
epidemiology, San Francisco, 1104
in HIV infection
cytokine responses in, 1554
interleukin-8 receptor expression in, 921
meningitis in, 473
viral replication in, cytokines in, 1332
meningitis in, rabbit model, 1563
osteomyelitis in, acute-phase response in, 1582
pathogenesis, mouse and guinea pig models, 1030
skin tests for, vs. *Mycobacterium avium* infections, 730
Tumor(s), cytomegalovirus, mouse model, 523
Tumor necrosis factor-$\alpha$
in bacteremia, *Mycobacterium avium* complex, in HIV infection, 1746
in bronchoalveolar lavage fluid, in influenza, pig model, 1076
down-regulation, in meningococcal infections, 1401
in *Escherichia coli* culture, vs. endotoxin release, 1302
in herpes simplex virus infections, recurrent, 827
in HIV infection, 905
in tuberculosis, 1332
in leishmaniasis, cutaneous, 1687
in mycobacterial meningitis, rabbit model, 1563
in osteomyelitis, 1582

peptidoglycan activation, 1629
*Plasmodium falciparum* induction, human immunodeficiency virus replication and, 437
in streptococcal group B infections, lactic acid effects on, 1418
synthesis, 774
in yellow fever vaccination, 774
Tumor necrosis factor receptor
in cerebrospinal fluid, in cerebral malaria, 1064
soluble, in dengue hemorrhagic fever, 778
Turpentine, inflammation from, interleukin-1 receptors in, mouse model, 1398
Typhus, scrub, dot blot immunoassay for, 800

Ulcer(s)
genital
*Haemophilus ducreyi*, prophylaxis, 1608
herpes simplex virus, acyclovir-resistant, 543
in HIV infection, 224, 481
peptic, risk factors for, 1124
Urease, *Helicobacter pylori*, in phagocytosis, 803
Urethritis, in HIV infection, 481
viral RNA in, 224
Urinary tract infections
adenovirus, in liver transplantation, 459
*Escherichia coli*
colonization, 1120
*papG* gene alleles in, 97
human leukocyte antigens in, 1296
red blood cell antigen phenotypes and, 1296
Urine
*Chlamydia trachomatis* in, molecular amplification assays for, 417
JC virus replication in, in HIV infection, 1502
Uveitis
*Leptospira*, polymerase chain reaction in, 1314
from rifabutin, 252
varicella-zoster virus, guinea pig model, 293

Vaccination
alphaviruses, 634
Argentine hemorrhagic fever, 277
chikungunya virus, 634
diphtheria-tetanus, during malaria prophylaxis, 1762
*Escherichia coli*
enterotoxigenic, 796
O157, 383
*Haemophilus influenzae*, 1112
oropharyngeal carriage and, 1758
herpes simplex virus
type 1, mouse model, 1451
type 2
guinea pig model, 1143
mouse model, 1155
human immunodeficiency virus, 301
canarypox vector in, 1230
cross-clade inhibition and, 1727
cytokine expression in, macaque model (simian immunodeficiency virus), 26
efficacy, 310
mouse model, 889
rhesus macaque model, 1247
influenza
vs. immunostimulating complexes, 1266
trivalent live cold-adapted, 1394
Japanese encephalitis virus, 221
Junin virus, 277
leishmaniasis, 1352
mouse model, 188
malaria, 1664
meningococci group B, 683
mucosal, herpes simplex virus type 1, mouse model, 1451
mumps, hemagglutinin-neuraminidase gene nucleotide sequence, 265
*Neisseria meningitidis*, 683
passive, simian immunodeficiency virus infection, 1247
*Plasmodium falciparum*, 1664
rabies, persistence, 1290
respiratory syncytial virus
bovine model, 874
in bronchopulmonary dysplasia, 467
rubella, arthropathy in, human leukocyte antigen associations with, 5
schistosomiasis, 1364
simian immunodeficiency virus, 26, 1247
*Staphylococcus aureus*, mouse model, 1013
streptococci, group B, serotype distribution, 998
*Streptococcus pneumoniae*, 1614
rat model, 986
tetanus-diphtheria, during malaria prophylaxis, 1762
varicella-zoster virus, persistence, 1701
Venezuelan equine encephalitis virus, 634
yellow fever, tumor necrosis factor-$\alpha$ synthesis after, 774
Vagina
HIV load in, 1214
microbicidal agents in, normal flora alterations from, 1386
Valaciclovir, prophylactic, for cytomegalovirus infections, in HIV infection, 48, 57
Vancomycin, resistance to, enterococci, genotyping, 368
Varicella-zoster virus
in major histocompatibility complex antigen down-regulation, 1390
vaccination, persistence, 1701
Venezuelan equine encephalitis virus, vaccination, 634
Venous thrombosis, in parenteral nutrition, in endotoxemia, 793
*Vibrio cholerae*, immune response to, in endemic region, 1594
Viral syncytial-inducing phenotype, as HIV infection prognostic indicator, 617
Virulence factors
*Candida albicans*, HIV antigens as, 1057
*Entamoeba histolytica*, neutral cysteine proteinase, 508
*Escherichia coli*, 642
in cystitis, 97
O157:H7, 1750
*papG* gene, 651
uropathogenic, 1120
*Helicobacter pylori*, in pediatric patients, 247
*Mycobacterium tuberculosis*, mouse and guinea pig models, 1030
streptococci group A, 1600
in skin infections, mouse model, 991
*Streptococcus pneumoniae*, 977
mouse model, 368
Visceral leishmaniasis
in HIV infection, monitoring, 1339
treatment, cytokine responses in, 815
Vitamin A, in HIV infection, 611
Vulva, herpes simplex virus infection, acyclovir-resistant, 543

Wasting syndrome, in microsporidiosis, treatment with TNP-470, mouse model, 515
Waterborne diseases
Brainerd diarrhea, 1041
*Escherichia coli* O157:H7 infections, 962
Wound infections, *Staphylococcus aureus*, guinea pig model, 701

X-linked agammaglobulinemia, GB virus C infection in, 1719

Yaws, differentiation from other treponemal diseases, 1036
Yeast killer toxin-like antibodies, candidacidal, 807
Yellow fever, vaccination, tumor necrosis factor-$\alpha$ synthesis after, 774

Zalcitabine, for HIV infection
  assessment with viral RNA levels, 40
  phenotypic variations in, 565
  resistance to, 1207, 1506
  virologic marker changes in, 625
Zidovudine, for HIV infection
  in combination therapy, viral RNA measurement in, 40
  mouse model, 337
  prophylactic, 557
  RANTES levels in, 1091
  resistance to, 557, 1207, 1521, 1730
  virus load measurement in, 1497
  virologic marker changes in, 625
Zinc-binding sequences, calprotectin, 812
Zymosan, inflammation from, interleukin-1 receptors in, mouse model, 1398